Ticker,Company,Type,Price,Market Cap,urls,Description,Phase 3 Ready,Phase 2b Ready,alzheimer
CDXI,Cardax Inc,Common Stock,1.26,$1.01M,https://finance.yahoo.com/quote/CDXI/profile?p=CDXI,"Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.",0,0,0
CHMJF,Chemistree Technology Inc,Common Stock,0.0412,$1.56M,https://finance.yahoo.com/quote/CHMJF/profile?p=CHMJF,"Chemistree Technology Inc., an investment company, operates in the cannabis sector in the United States. The company was formerly known as Whattozee Networks Inc. and changed its name to Chemistree Technology Inc. in August 2017. Chemistree Technology Inc. was incorporated in 2008 and is headquartered in North Vancouver, Canada.",0,0,0
ENDV,Endonovo Therapeutics Inc,Common Stock,0.02865,$1.68M,https://finance.yahoo.com/quote/ENDV/profile?p=ENDV,"Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its electrocuetical medical devices are also used for the treatment of inflammation, wounds, cardiovascular diseases, chronic kidney diseases, liver diseases, non-alcoholic steatohepatitis, peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post- concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.",0,0,0
CAPS,Capstone Therapeutics Corp,Common Stock,36.01,$1.94M,https://finance.yahoo.com/quote/CAPS/profile?p=CAPS,"Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.",0,0,0
RSPI,RespireRx Pharmaceuticals Inc,Common Stock,0.0225,$2.60M,https://finance.yahoo.com/quote/RSPI/profile?p=RSPI,"RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the nervous system's endogenous cannabinoid receptors for use in refractory chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression (RD), as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, SCI, neurological diseases, and orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.",0,1,0
KDCE,Kid Castle Educational Corp,Common Stock,0.003,$2.77M,https://finance.yahoo.com/quote/KDCE/profile?p=KDCE,"Kid Castle Educational Corporation operates and manages a portfolio of biopharmaceutical, agricultural, and pureplay cannabidiol (CBD) assets in the United States of America. It extracts, purchases, and distributes bulk pure CBD, isolate, hemp oil, THC-free CBD distillate, and crude CBD Oil. The company was formerly known as King Ball International Technology Corporation and changed its name to Kid Castle Educational Corporation in August 2002. Kid Castle Educational Corporation was incorporated in 1985 and is headquartered in Torrance, California.",0,0,0
RASP,Rasna Therapeutics Inc,Common Stock,0.05,$3.45M,https://finance.yahoo.com/quote/RASP/profile?p=RASP,"Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia. It focuses on developing molecule drug candidates targeting NPM1 and LSD1, which are implicated in the disease progression of leukemia and lymphoma. The company is developing RASP-201 (LSD1), an enzyme that demethylates lysine side chain of histones; and RASP-301, an NPM1 gene that provides instructions for making nucleophosmin protein. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York.",0,0,0
SGBI,Sangui Biotech International Inc,Common Stock,0.0168,$3.48M,https://finance.yahoo.com/quote/SGBI/profile?p=SGBI,"Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. The company's artificial oxygen carriers provide oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia, or blood loss, as well as chronic wounds. It also offers nano formulations for the regeneration of skin, including skin moisturization and enhanced skin elasticity; Chitoskin wound pads for supporting wound healing; and Hemospray wound spray, a medical product that is used for the healing of chronic wounds. The company sells its wound spray products under the Granulox brand name primarily in Europe and Mexico; and cosmetics products through internet shop. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.",0,0,0
KAYS,Kaya Holdings Inc,Common Stock,0.2845,$3.75M,https://finance.yahoo.com/quote/KAYS/profile?p=KAYS,"Kaya Holdings, Inc., a vertically integrated legal marijuana enterprise, produces, distributes, and/or sells a range of cannabis products in the United States. The company offers flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. It also operates two retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. The company also provides standing display cases with cannabis intended glassware under the Really Happy Glass brand; and t-shirt designs under the Kaya Gear brand name. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. was incorporated in 1993 and is headquartered in Fort Lauderdale, Florida.",0,0,0
POTVF,Potent Ventures Inc,Common Stock,0.0389,$3.80M,https://finance.yahoo.com/quote/POTVF/profile?p=POTVF,"Potent Ventures Inc. sells branded cannabis packaging. It offers its products through Wknd! and Orchard Heights brand name. The company was formerly known as Weekend Unlimited Industries Inc. and changed its name to Potent Ventures Inc. in April 2021. Potent Ventures Inc. is based in Vancouver, Canada.",0,0,0
NPTX,Neuropathix Inc,Common Stock,0.0482,$3.84M,https://finance.yahoo.com/quote/NPTX/profile?p=NPTX,"Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary cannabinoid product platform. It engages in the research and development of chemical entities, such as KLS-13019, KLS-13023, and KLS-13022, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of chemotherapy induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. The company was formerly known as Kannalife, Inc. and changed its name to Neuropathix, Inc. in November 2020. Neuropathix, Inc. was founded in 2010 and is based in Doylestown, Pennsylvania.",0,0,0
ISCO,International Stem Cell Corp,Common Stock,0.51,$4.21M,https://finance.yahoo.com/quote/ISCO/profile?p=ISCO,"International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company's human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was incorporated in 2005 and is headquartered in Carlsbad, California.",0,0,0
NXEN,Nexien BioPharma Inc,Common Stock,0.081,$4.70M,https://finance.yahoo.com/quote/NXEN/profile?p=NXEN,"Nexien BioPharma, a pharmaceutical company, engages in the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, and pre-clinical and clinical pathways to address a range of medical conditions and disorders. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.",0,0,0
FNNZF,FinCanna Capital Corp,Common Stock,0.0471,$4.87M,https://finance.yahoo.com/quote/FNNZF/profile?p=FNNZF,"FinCanna Capital Corp. operates as a royalty company for the licensed cannabis industry in the United States. It provides financing for companies operating in the cannabis sector. The company has royalty agreements with Green Compliance Inc.; QVI, Inc.; and Cultivation Technologies, Inc. FinCanna Capital Corp. was incorporated in 2016 is headquartered in Vancouver, Canada.",0,0,0
VNNYF,Vinergy Capital Inc,Common Stock,0.0679,$4.98M,https://finance.yahoo.com/quote/VNNYF/profile?p=VNNYF,"Vinergy Capital Inc. does not have significant operations. Previously, it was engaged in the development of cannabis products. The company was formerly known as Vinergy Cannabis Capital Inc. and changed its name to Vinergy Capital Inc. in March 2021. Vinergy Capital Inc. is headquartered in Vancouver, Canada.",0,0,0
QRON,Qrons Inc,Common Stock,0.44,$5.85M,https://finance.yahoo.com/quote/QRON/profile?p=QRON,"Qrons Inc., a biotechnology company, develops biotech products, treatments, and technologies that to combat neuronal diseases. Its product candidates include QS100, an injury specific, 3D printable, implantable mesenchymal stem cells (MSCs)-synthetic hydrogel to treat penetrating brain injuries; and QS200, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries. The company was formerly known as BioLabMart Inc. and changed its name to Qrons Inc. in August 2017. Qrons Inc. was incorporated in 2016 and is based in New York, New York.",0,0,0
IPCIF,IntelliPharmaCeutics International Inc,Common Stock,0.1605,$5.96M,https://finance.yahoo.com/quote/IPCIF/profile?p=IPCIF,"Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; and Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Pristiq, a desvenlafaxine extended-release tablet to treat depression; and Regabatin XR and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain. In addition, the company offers Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, it is developing Oxycodone ER, an extended release tablet for relief of pain. The company has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.",0,0,0
WPHM,Winston Pharmaceuticals Inc,Common Stock,0.08,$6.19M,https://finance.yahoo.com/quote/WPHM/profile?p=WPHM,"Winston Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and commercializes therapeutics for pain management. It focuses on pain indications, such as episodic cluster headache, chronic migraine headache, neuropathic pain syndromes, osteo-and rheumatoid arthritis, and pain and inflammation in inflammatory bowel disease, as well as niche indications. Winston Pharmaceuticals, Inc. was formerly known as Winston Laboratories, Inc. and changed its name to Winston Pharmaceuticals, Inc. in November 2008. The company was incorporated in 1998 and is headquartered in Vernon Hills, Illinois.",0,0,0
BIOIF,Biome Grow Inc,Common Stock,0.06144,$6.38M,https://finance.yahoo.com/quote/BIOIF/profile?p=BIOIF,"Biome Grow Inc. focuses on the cannabis business. The company is headquartered in Toronto, Canada.",0,0,0
HCYT,H-CYTE Inc,Common Stock,0.045,$6.51M,https://finance.yahoo.com/quote/HCYT/profile?p=HCYT,"H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute biologics for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.",0,0,0
MGWFF,Leaf Green World Inc,Common Stock,0.03726,$6.52M,https://finance.yahoo.com/quote/MGWFF/profile?p=MGWFF,"Maple Leaf Green World Inc., together with its subsidiaries, focuses on the cannabis and industry in North America. The company was formerly known as Maple Leaf Reforestation Inc. and changed its name to Maple Leaf Green World Inc. in October 2012. Maple Leaf Green World Inc. is headquartered in Calgary, Canada.",0,0,0
MMJFF,Matica Enterprises Inc,Common Stock,0.0286,$8.14M,https://finance.yahoo.com/quote/MMJFF/profile?p=MMJFF,"Matica Enterprises Inc. engages in the medical marijuana business. It offers IONIC MIST, a spray mist that captures and neutralizes cannabis smoke odours. The company was formerly known as Matica Graphite Inc. and changed its name to Matica Enterprises Inc. in July 2014. Matica Enterprises Inc. was incorporated in 2007 and is based in Toronto, Canada.",0,0,0
CVGRF,City View Green Holdings Inc,Common Stock,0.0487,$8.62M,https://finance.yahoo.com/quote/CVGRF/profile?p=CVGRF,"City View Green Holdings Inc. intends to produce cannabis-infused food, oils, distillates, and water-soluble products for the food and beverage markets. The company is headquartered in Toronto, Canada.",0,0,0
CBDY,Target Group Inc,Common Stock,0.018,$9.18M,https://finance.yahoo.com/quote/CBDY/profile?p=CBDY,"Target Group Inc. cultivates, processes, and distributes curated cannabis products for the adult-use medical and recreational cannabis market in Canada. Its products include cannabis flower and extract pods for vaporizer use, cannabis pre-rolls, k-cup infused coffee and tea pods, infused cannabis beverages and edibles, infused topical products, and CBD wellness products. The company also offers Wisp, a single-use pre-measured pod and vaporizer system for consumers involved in vaporizing natural herbs, including cannabis. It has a collaboration agreement with cGreen, Inc for manufacturing and distributing the patent-pending THC antidote True Focus in the United States, Europe, and the Caribbean; and distribution, collaboration, and licensing agreement with Serious Seeds B.V. The company was formerly known as Chess Supersite Corporation and changed its name to Target Group Inc. in July 2018. Target Group Inc. was incorporated in 2013 and is based in Hamilton, Canada.",0,0,0
TDLAF,TBG Diagnostics Ltd,Common Stock,0.0471,$10.25M,https://finance.yahoo.com/quote/TDLAF/profile?p=TDLAF,"TBG Diagnostics Limited, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits, instruments, and services in Taiwan and China. It provides ExProbe HLA and HPA kits for human leukocyte antigen (HLA) and human platelet antigens (HPA) allele genotyping, which uses real time polymerase chain reaction (PCR) techniques with sequence specific primers and probes; Morgan SSP HLA kits for determining HLA alleles using PCR techniques with sequence specific primers; HLAssure SBT HLA Kits for transplantation donor selection; and AccuType SBT analysis software to analyze sequences from all ab1 based files. The company also offers Morgan SSPal HLA Typing Analysis Software, a gel result interpretation software; HLA typing services that offer low to high resolution using PCR fragment analysis (SSP) and DNA sequencing (SBT); QPCR Q6000, a six-channel real time PCR instrument; QzNGS NGS that provides high resolution HLA genotyping; and COVID-19 testing kits. It serves clinical labs, blood centers, and bone marrow registry labs. The company was formerly known as Progen Pharmaceuticals Limited and changed its name to TBG Diagnostics Limited in December 2015. TBG Diagnostics Limited was incorporated in 1989 is based in Greenslopes, Australia.",0,0,0
CANB,Can B Corp,Common Stock,0.66,$10.58M,https://finance.yahoo.com/quote/CANB/profile?p=CANB,"Can B Corp. produces and sells cannabidiol (CBD) based products in the United States. It provides CBD products derived from hemp, including oils, creams, moisturizers, isolate, gel caps, spa products, and concentrates through its Website and vending machines, and other medical professionals. The company was formerly known as Canbiola Inc. and changed its name to Can B Corp. in February 2020. Can B Corp. was incorporated in 2005 and is based in Hicksville, New York.",0,0,0
BBRRF,Blueberries Medical Corp,Common Stock,0.08,$11.10M,https://finance.yahoo.com/quote/BBRRF/profile?p=BBRRF,"Blueberries Medical Corp. engages in the growth, cultivation, development, production, and supply of medicinal cannabis and related products in Colombia. It offers medicinal-grade cannabis oil extracts and related products. The company is headquartered in BogotÃ¡, Colombia.",0,0,0
SRUTF,Sproutly Canada Inc,Common Stock,0.04095,$11.18M,https://finance.yahoo.com/quote/SRUTF/profile?p=SRUTF,"Sproutly Canada Inc. produces and supplies water-soluble cannabis solutions and bio-natural oils to beverage and consumable markets in Canada. It offers its products under the Caliber brand name. The company is based in Vancouver, Canada.",0,0,0
EXDI,Exactus Inc,Common Stock,0.101,$11.38M,https://finance.yahoo.com/quote/EXDI/profile?p=EXDI,"Exactus, Inc. produces and supplies hemp and hemp-derived products in the United States. It provides cannabidiol (CBD) feminized genetics, high cannabigerol (CBG) feminized genetics, hemp-derived specialty ingredients, and white-label products to the cosmetic, wellness, food, beverage, pharmaceutical, and pet industries. The company's specialty ingredients include CBD, CBG, CBN, and CBC isolates; CBD and CBG distillates; CBD water-soluble; CBD and CBG biomass; CBD AND CBG flowers; and CBD crude oil. It also provides a range of custom manufactured specialty cannabinoid products, such as skincare products, pain creams, tinctures, bath bombs, soft gels, balms, pet products, supplements, and other products. The company is based in Delray Beach, Florida. Exactus, Inc. is a subsidiary of Ceed2Med, LLC.",0,0,0
MRVFF,Nuvo Pharmaceuticals Inc,Common Stock,1.05,$11.50M,https://finance.yahoo.com/quote/MRVFF/profile?p=MRVFF,"Nuvo Pharmaceuticals Inc. provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial; Cambia, a nonsteroidal anti-inflammatory drug for migraine; Suvexx/Treximet migraine medicine; NeoVisc viscosupplement for knee osteoarthritis; and Resultz/FullMarks/LAUSBUB for head lice infestations. The company also provides Bezalip SR for patients with high cholesterol or high levels of triglycerides; Proferrin, an iron supplement for the prevention and treatment of iron deficiency; Fiorinal 1 and Fiorinal C1 for the relief of tension-type headaches; Viskazide and Visken antihypertensive agents; Collatamp G for surgical implantation during surgery; PegaLAX, a laxative for the treatment of occasional constipation and irregularity; Mutaflor, a probiotic for the management and relief of chronic constipation and associated abdominal pain and cramps; MoviPrep for the cleansing of the colon in preparation for colonoscopy; Uracyst for mild to severe GAG layer damage of the urinary bladder; and Soriatane to treat psoriasis and other keratinization disorders. In addition, it offers Pennsaid and Pennsaid 2% topical treatments for osteoarthritic pain; Vimovo for relief of arthritis symptoms; SYNERA/RAPYDAN topical patches used to help prevent pain associated with needle sticks and other superficial skin procedures; Yosprala for the prevention of heart attacks and strokes; and Heated Lidocaine/Tetracaine Patch, a topical patch applied prior to painful medical procedures. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was founded in 1983 and is headquartered in Mississauga, Canada.",0,0,0
NMLSF,Nova Mentis Life Sciences Corp,Common Stock,0.11,$12.09M,https://finance.yahoo.com/quote/NMLSF/profile?p=NMLSF,"Nova Mentis Life Science Corp., through its subsidiaries, engages in the research and development of medicinal psychedelics for neuroinflammatory conditions with a focus on autism spectrum disorder in Canada. It is also involved in the research and development of psychedelic medicines for metabolic indications, such as obesity and diabetes; and development of cannabis products. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is headquartered in Vancouver, Canada.",0,0,0
FIORF,Fiore Cannabais Ltd,Common Stock,0.0731,$12.49M,https://finance.yahoo.com/quote/FIORF/profile?p=FIORF,"Fiore Cannabis Ltd. engages in the cultivation and production of medical and recreational marijuana in Canada and the United States. The company was formerly known as Citation Growth Corp. and changed its name to Fiore Cannabis Ltd. in November 2020. Fiore Cannabis Ltd. was incorporated in 2007 and is headquartered in Kelowna, Canada.",0,0,0
AQSZF,Aequus Pharmaceuticals Inc,Common Stock,0.1,$12.52M,https://finance.yahoo.com/quote/AQSZF/profile?p=AQSZF,"Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid-based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.",0,0,0
SNOA,Sonoma Pharmaceuticals Inc,Common Stock,6.53,$12.86M,https://finance.yahoo.com/quote/SNOA/profile?p=SNOA,"Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as Loyon for the management of skin scaling. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products designed to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH and MicrocynVS, which are HOCl-based solutions designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Pediacyn, Epicyn, Gramaderm, and Microdacyn for dermatoses, scar management, and acne; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.",0,0,0
OWPC,One World Pharma Inc,Common Stock,0.2205,$13.52M,https://finance.yahoo.com/quote/OWPC/profile?p=OWPC,"One World Pharma, Inc. focuses on producing and manufacturing raw cannabis and hemp plant ingredients for medical and industrial uses worldwide. It intends to cultivate, process, and supply crude cannabis oil, distillate, and isolate to customers' specification, as well as hemp plant biomass. The company was founded in 2017 and is headquartered in Las Vegas, Nevada.",0,0,0
THCBF,THC Biomed International Ltd,Common Stock,0.085,$13.54M,https://finance.yahoo.com/quote/THCBF/profile?p=THCBF,"THC Biomed Intl Ltd. produces and sells medical and recreational cannabis in Canada. The company conducts research and development of products and services related to the medical cannabis industry. It also offers cannabis beverage under the THC KISS brand name, as well as pure cannabis sticks. The company was founded in 2012 and is headquartered in Kelowna, Canada.",0,0,0
MHTX,Manhattan Scientifics Inc,Common Stock,0.025,$14.68M,https://finance.yahoo.com/quote/MHTX/profile?p=MHTX,"Manhattan Scientifics, Inc., a technology incubator, develops and commercializes life-enhancing technologies in the United States. It develops technologies in the areas of nano-technologies and nano-medicine. The company was formerly known as Grand Enterprises, Inc. Manhattan Scientifics, Inc. was founded in 1992 and is based in New York, New York.",0,0,0
SBUDF,Sugarbud Craft Growers Corp,Common Stock,0.0319,$14.98M,https://finance.yahoo.com/quote/SBUDF/profile?p=SBUDF,"SugarBud Craft Growers Corp. engages in the development, production, distribution, and sale of cannabis products in Canada. The company was formerly known as Relentless Resources Ltd. and changed its name to SugarBud Craft Growers Corp. in October 2018. SugarBud Craft Growers Corp. is headquartered in Calgary, Alberta.",0,0,0
GBLX,GB Sciences Inc,Common Stock,0.0496,$14.99M,https://finance.yahoo.com/quote/GBLX/profile?p=GBLX,"GB Sciences, Inc. engages in the research and development of cannabinoid medicines in North America and Europe. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.",0,0,0
BICTF,Biocure Technology Inc,Common Stock,0.145,$15.46M,https://finance.yahoo.com/quote/BICTF/profile?p=BICTF,"Biocure Technology Inc. develops and commercializes biopharmaceutical technologies for uses in recombinant and ranibizumab. The company is developing Interferons- Ã for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It is also developing CAR T Cell Therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; and hair growth products. Biocure Technology Inc. was founded in 2005 and is headquartered in Vancouver, Canada.",0,0,0
BSTG,Biostage Inc,Common Stock,1.65,$15.49M,https://finance.yahoo.com/quote/BSTG/profile?p=BSTG,"Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.",0,0,0
BIOAF,biOasis Technologies Inc,Common Stock,0.22146,$15.87M,https://finance.yahoo.com/quote/BIOAF/profile?p=BIOAF,"Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the delivery of therapeutics across the blood-brain barrier (BBB); and the treatment of central nervous system disorders, including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-002), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). Bioasis Technologies Inc. has a research collaboration with Aposense Ltd. to focus on the delivery of siRNA into the brain. The company was founded in 2007 and is based in New Haven, Connecticut.",0,0,0
PLPRF,Plus Products Inc,Common Stock,0.367,$15.92M,https://finance.yahoo.com/quote/PLPRF/profile?p=PLPRF,"Plus Products Inc. develops, manufactures, and sells cannabis products in California. It offers cannabis-infused edibles to the regulated medicinal and adult-use, or recreational markets. The company sells products under the PLUS brand to dispensaries and delivery service customers. Plus Products Inc. was incorporated in 2018 and is headquartered in Vancouver, Canada.",0,0,0
KNBIF,Kane Biotech Inc,Common Stock,0.14,$16.07M,https://finance.yahoo.com/quote/KNBIF/profile?p=KNBIF,"Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; medical device coatings under the Aledex name; and shampoos for dogs, cats, and horses under the Alosera name. It also offers anti-itch shampoo under the silkstem name; scalp detoxifiers, shampoos, and shampoo bars under the DermaKB Biofilm brand name; and wound care products under the Coactiv+ name. The company was incorporated in 2001 and is based in Winnipeg, Canada.",0,0,0
NTEC,Intec Pharma Ltd,Common Stock,9.15,$16.68M,https://finance.yahoo.com/quote/NTEC/profile?p=NTEC,"Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which has completed a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck Sharp & Dohme for the development of Accordion Pill; and a cannabinoid research collaboration agreement with GW Research Limited to explore an undisclosed research program using the Accordion Pill platform. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was incorporated in 2000 and is based in Jerusalem, Israel.",1,1,0
CHOOF,Choom Holdings Inc,Common Stock,0.051,$16.99M,https://finance.yahoo.com/quote/CHOOF/profile?p=CHOOF,"Choom Holdings Inc., through its subsidiaries, engages in the retail of cannabis. As of June 30, 2020, the company operates two medical and two coaching clinics under the name Concord Medical Centre; and 13 retail stores. The company was formerly known as Standard Graphite Corporation and changed its name to Choom Holdings Inc. in November 2017. Choom Holdings Inc. was incorporated in 2006 and is based in Vancouver, Canada.",0,0,0
KOAN,Resonate Blends Inc,Common Stock,0.445,$17.44M,https://finance.yahoo.com/quote/KOAN/profile?p=KOAN,"Resonate Blends, Inc., a cannabis holding company, provides cannabis-based products. It also operates an online mobile marketing platform that provides various offers, discounts, and alerts and events schedules, such as happy hours, trivia night, and other campaigns. The company was formerly known as Textmunication Holdings, Inc. and changed its name to Resonate Blends, Inc. in December 2019. Resonate Blends, Inc. is based in Calabasas, California.",0,0,0
VIVXF,Avivagen Inc,Common Stock,0.31,$17.66M,https://finance.yahoo.com/quote/VIVXF/profile?p=VIVXF,"Avivagen Inc., a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers products based on its OxC-Beta technology, such as OxC-beta Livestock, a premix for livestock feeds; and Vivamune Health Chews supplements for companion animals. It has operations in Mexico and Latin America. The company was formerly known as Chemaphor, Inc. and changed its name to Avivagen Inc.in May 2012. Avivagen Inc. was founded in 2005 and is headquartered in Ottawa, Canada.",0,0,0
SXTC,China SXT Pharmaceuticals Inc,Common Stock,1.26,$18.31M,https://finance.yahoo.com/quote/SXTC/profile?p=SXTC,"China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. It offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. The company provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of May 2, 2020, it served 116 pharmaceutical companies, 56 pharmacies, and 76 hospitals. The company was founded in 2005 and is based in Taizhou, China.",0,0,0
SNES,SenesTech Inc,Common Stock,1.52,$18.40M,https://finance.yahoo.com/quote/SNES/profile?p=SNES,"SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. The company offers ContraPest, a liquid bait that limits reproduction of male and female rats. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.",0,0,0
GPFT,Grapefruit USA Inc,Common Stock,0.04,$19.66M,https://finance.yahoo.com/quote/GPFT/profile?p=GPFT,"Grapefruit USA, Inc. focuses on manufacturing and distribution of cannabis distillates, edibles, and cannabis products. It also offers cannabis advisory services for branding, compliance, packaging, extraction, edible manufacturing, and distribution logistics efforts. The company was formerly known as Grapefruit Boulevard Investments, Inc. and changed its name to Grapefruit USA, Inc. in January 2020. Grapefruit USA, Inc. was founded in 2017 and is based in Wilmington, Delaware.",0,0,0
BETRF,Betterlife Pharma Inc,Common Stock,0.255,$20.07M,https://finance.yahoo.com/quote/BETRF/profile?p=BETRF,"BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus. BetterLife Pharma Inc. has a research agreement with the University of California San Diego for preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.",0,0,0
INM,InMed Pharmaceuticals Inc,Common Stock,2.71,$21.34M,https://finance.yahoo.com/quote/INM/profile?p=INM,"InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.",0,0,0
CLSH,CLS Holdings USA Inc,Common Stock,0.16613,$21.63M,https://finance.yahoo.com/quote/CLSH/profile?p=CLSH,"CLS Holdings USA, Inc., a diversified cannabis company, focuses on the extraction and conversion of cannabinoids in the United States. The company extracts various cannabinoids from the cannabis plants and converts into concentrates, such as oils, waxes, edibles, and shatters. Its concentrates are used for electronic cigarettes vaporization, and pharmaceutical and other purposes. The company also offers consulting services to cannabis-related businesses comprising growers, dispensaries, and laboratories; and toll processing services. CLS Holdings USA, Inc. was founded in 2014 and is based in Las Vegas, Nevada.",0,0,0
TGIFF,1933 Industries Inc,Common Stock,0.069,$21.92M,https://finance.yahoo.com/quote/TGIFF/profile?p=TGIFF,"1933 Industries Inc., a cannabis company, engages in the cultivation and production of medical marijuana in the United States and Canada. It operates in AMA and Infused MFG segments. The company operates in the medical and recreational cannabis sectors. It also provides cannabidiol infused products, such as tinctures, lotions, creams, vape pens, cartridges, lip balms, tetrahydrocannabinol concentrates, hemp-seed oils, and capsules under Canna Hemp, Canna Hemp X, Canna Hemp PLUS, Canna Hemp HEMP, and Canna Fused brands; and cannabis flowers and concentrates. The company was formerly known as Friday Night Inc. and changed its name to 1933 Industries Inc. in September 2018. 1933 Industries Inc. was incorporated in 2008 and is headquartered in Vancouver, Canada.",0,0,0
VRPX,Virpax Pharmaceuticals Inc,Common Stock,4.4,$22.22M,https://finance.yahoo.com/quote/VRPX/profile?p=VRPX,"Virpax Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company, develops and manufactures non-opioid and non-addictive pharmaceutical products using drug delivery systems for pain management. The company offers products, such as Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; Probudur (LBL100), long-acting bupivacaine liposomal gel for postoperative pain management; OSF200 for chronic osteoarthritis of the knee; and NES100 (Envelta), an exogenous enkephalin intranasal spray for acute and chronic pain. It also develops PES200 for the management of post-traumatic stress disorder; and MMS019 high-density molecular masking spray to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.",0,0,0
OILFF,Nextleaf Solutions Ltd,Common Stock,0.1775,$22.74M,https://finance.yahoo.com/quote/OILFF/profile?p=OILFF,"Nextleaf Solutions Ltd., a cannabis extraction technology company, develops and licenses technology for the extraction, distillation, and formulation of cannabinoids in Canada. It also extracts, distills, purifies, delivers, and wholesales CBD oils and THC cannabinoid ingredients; researches and develops cannabis infused products, vapes, ingestible concentrates, and specialty extracts; and provides extraction services. The company was founded in 2015 and is headquartered in Vancouver, Canada.",0,0,0
TTNP,Titan Pharmaceuticals Inc,Common Stock,2.325,$22.88M,https://finance.yahoo.com/quote/TTNP/profile?p=TTNP,"Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program, TP-2021 for use in combination with ProNeura technology for treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including non-clinical evaluation of the ProNeura platform in malaria prophylaxis. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.",0,0,0
ACAN,Americann Inc,Common Stock,0.99,$22.99M,https://finance.yahoo.com/quote/ACAN/profile?p=ACAN,"AmeriCann, Inc. operates as a specialized cannabis company in the United States. It intends to design, develop, lease, and operate cultivation, processing, and manufacturing facilities for licensed cannabis businesses in the United States. The company was formerly known as Nevada Health Scan, Inc. and changed its name to AmeriCann, Inc. in 2014. AmeriCann, Inc. was founded in 2010 and is based in Denver, Colorado.",0,0,0
PSTV,Plus Therapeutics Inc,Common Stock,1.96,$23.57M,https://finance.yahoo.com/quote/PSTV/profile?p=PSTV,"Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.",0,0,0
QBIO,Q BioMed Inc,Common Stock,0.85,$23.59M,https://finance.yahoo.com/quote/QBIO/profile?p=QBIO,"Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies; and Metastron, a radiopharmaceutical drug for metastatic cancer bone pain therapy. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research for the development of novel Covid-19 therapeutics. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.",0,0,0
MYMX,Mymetics Corp,Common Stock,0.07555,$23.69M,https://finance.yahoo.com/quote/MYMX/profile?p=MYMX,"Mymetics Corporation, a vaccine company, focuses on researching and developing vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, malaria, Covid-19, intra nasal influenza, respiratory syncytial virus, and chikungunya. It has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.",0,0,0
PALI,Palisade Bio Inc,Common Stock,3.48,$23.95M,https://finance.yahoo.com/quote/PALI/profile?p=PALI,"Leading BioSciences, Inc. develops therapeutics to improve human health through therapeutic protection of the gastrointestinal mucosal barrier. The company was founded in 2005 and is based in Carlsbad, California.",0,0,0
SONN,Sonnet BioTherapeutics Holdings Inc,Common Stock,1.12,$23.95M,https://finance.yahoo.com/quote/SONN/profile?p=SONN,"Sonnet BioTherapeutics Holdings, Inc., an oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding (FHAB) technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate includes SON-080, a human version of low dose Interleukin-6 (IL-6), which has completed Phase I trials for the treatment of patients with chemotherapy-induced peripheral neuropathy. The company is also developing SON-081, a low dose IL-6 for the treatment of patients with diabetic peripheral neuropathy and is under phase I trials; SON-1010, a FHAB derived compound, which utilizes a human version of Interleukin-12 (IL-12) is under pre-clinical trial, as well as SON-1210, a bi-specific construct that combines FHAB with IL-12 and human Interleukin-15 for the treatment of solid tumor is under pre-clinical trial. In addition, it develops SON-2014, a bi-specific combination of granulocyte-macrophage colony stimulating factor and Interleukin-18 for the treatment of cancer; and SON-3015, a bi-specific combination of anti-IL6 and anti-tumor growth factor beta for tumor and bone metastases. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.",0,0,0
CNBX,Cannabics Pharmaceuticals Inc,Common Stock,0.17,$24.49M,https://finance.yahoo.com/quote/CNBX/profile?p=CNBX,"Cannabics Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. The company focuses on developing and marketing bioinformatic delivery systems for cannabinoids, personalized medicine therapies, and procedures based on cannabis originated compounds and bioinformatics tools. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, a drug sensitivity test for cannabinoid-based cancer therapies. The company was formerly known as American Mining Corporation and changed its name to Cannabics Pharmaceuticals Inc. in May 2014. Cannabics Pharmaceuticals Inc. was founded in 2004 and is based in Bethesda, Maryland. Cannabics Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.",0,0,0
BLCM,Bellicum Pharmaceuticals Inc,Common Stock,3.08,$24.52M,https://finance.yahoo.com/quote/BLCM/profile?p=BLCM,"Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes when administered after hematopoietic stem cell transplantation in the treatment of hematologic malignancies and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.",0,0,0
PHIO,Phio Pharmaceuticals Corp,Common Stock,1.82,$24.63M,https://finance.yahoo.com/quote/PHIO/profile?p=PHIO,"Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762, which targets the checkpoint protein PD-1 that prevent T cells from attacking various cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that prevent cancer cells from inactivating T cells and attack the cancer. It has collaboration with AgonOx, Inc. on clinical development of novel immunotherapy drugs targeting key regulators of the immune response to cancer. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.",0,0,0
ARTL,Artelo Biosciences Inc,Common Stock,1.05,$25.23M,https://finance.yahoo.com/quote/ARTL/profile?p=ARTL,"Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences has research collaboration with Trinity College Dublin to Investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is headquartered in La Jolla, California.",0,0,0
EYEG,Eyegate Pharmaceuticals Inc,Common Stock,3.21,$26.76M,https://finance.yahoo.com/quote/EYEG/profile?p=EYEG,"EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop, which is in Phase I safety study for multiple diseases that affect the ocular surface and anterior region of the eye, comprising of allergic conjunctivitis, viral conjunctivitis, and dry eye disease. The company also develops ocular bandage gel, a modified form of the natural polymer hyaluronic acid for corneal wound repair, and punctate epitheliopathies with a focus on dry eye. The company has license agreements with BioTime, Inc. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.",0,0,0
VEXTF,Vext Science Inc,Common Stock,0.5889,$27.15M,https://finance.yahoo.com/quote/VEXTF/profile?p=VEXTF,"Vext Science, Inc., through its subsidiaries, operates as an integrated agricultural technology, services, and property management company in the cannabis industry in the United States. The company is involved in the cultivation, extraction, manufacture, and sale of THC and CBD cartridges, concentrates, and edibles. It also engages in the retail dispensary activities; and wholesale distribution of cannabis THC and hemp CBD products under the Vapen and Pure Touch Botanicals brands. In addition, the company offers Vapen clear infused products, THC chocolate bars, THC syrup, THC snacks, candies, and gummies under Vapen Kitchens brand. The company was formerly known as Vapen MJ Ventures Corporation and changed its name to Vext Science, Inc. in November 2019. Vext Science, Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.",0,0,0
GNBT,Generex Biotechnology Corp,Common Stock,0.2313,$27.39M,https://finance.yahoo.com/quote/GNBT/profile?p=GNBT,"Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida.",0,1,0
NBY,NovaBay Pharmaceuticals Inc,Common Stock,0.6404,$27.48M,https://finance.yahoo.com/quote/NBY/profile?p=NBY,"NovaBay Pharmaceuticals, Inc., a medical device company, develops products for the eye care markets in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx Clinical Reset, a gentle and soothing facial spray; and NeutroPhase and PhaseOne for the wound care market. It also offers KN95 Masks. The company sells its products through distribution partners, as well as offers Avenova and CelleRx Clinical Reset through online sales channels. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.",0,0,0
GOVX,Geovax Labs Inc,Common Stock,5.09,$27.59M,https://finance.yahoo.com/quote/GOVX/profile?p=GOVX,"GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Geneva Foundation; the University of California; and Leidos, Inc. GeoVax Labs, Inc. was incorporated in 2001 and is based in Smyrna, Georgia.",0,0,0
XBIO,Xenetic Biosciences PLC,Common Stock,3.185,$27.73M,https://finance.yahoo.com/quote/XBIO/profile?p=XBIO,"Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.",0,0,0
PVCT,Provectus Biopharmaceuticals Inc,Common Stock,0.069,$28.05M,https://finance.yahoo.com/quote/PVCT/profile?p=PVCT,"Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal disodium (cGMP RBD) for the treatment of adult solid tumor cancers, such as head and neck, breast, pancreatic, liver, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; and multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.",0,0,0
VLON,Vallon Pharmaceuticals Inc,Common Stock,4.02,$28.55M,https://finance.yahoo.com/quote/VLON/profile?p=VLON,"Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.",0,0,0
AVCNF,Avicanna Inc,Common Stock,0.7,$28.89M,https://finance.yahoo.com/quote/AVCNF/profile?p=AVCNF,"Avicanna Inc., a biopharmaceutical company, focuses on the research, development, cultivation, manufacture, and commercialization of plant-derived cannabinoid-based products and extracts for the use in medical, consumer health, and pharmaceutical industries internationally. The company provides pharmaceutical grade cannabinoids, including tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), and other rare cannabinoids; active pharmaceutical ingredients (APIs); feminized seeds; and bulk formulations under the Aureus Santa Marta brand. It also offers CBD based derma-cosmetic consumer products, such as beauty treatment, moisture and protection, and specialized care products under the Pura Earth brand; and medical cannabis/phyto-therapeutic products for the medical or homeopathic use under the Rho Phyto brand. In addition, the company provides pharmaceutical products focusing on skin disorders, including epidermolysis bullosa, eczema, and general skin problems comprising acne, erythema, and dryness; and neurological disorders, such as neuropathic pain, epilepsy, Parkinson's disease and multiple sclerosis, and nociceptive pain resulting from inflammatory and joint disorders, as well as a topical cream for rare genetic skin disorders. Avicanna has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based pharmaceutical for the treatment of COVID-19 induced lung inflammation. Avicanna Inc.was founded in 2016 and is headquartered in Toronto, Canada.",0,0,0
BNTC,Benitec Biopharma Ltd,Common Stock,3.67,$29.22M,https://finance.yahoo.com/quote/BNTC/profile?p=BNTC,"Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.",0,0,0
EXPFF,Citizen Stash Cannabis Corp,Common Stock,0.2888,$29.23M,https://finance.yahoo.com/quote/EXPFF/profile?p=EXPFF,"Citizen Stash Cannabis Corp., through its subsidiaries, engages in the production, distribution, and sale of cannabis products in Canada. Its products are used for adult-use, wellness and therapeutic, and medical applications. Experion Holdings Ltd. offers its products under the Citizen Stash and Kanabe brand names. The company was formerly known as Experion Holdings Ltd. and changed its name to Citizen Stash Cannabis Corp. in June 2021. Citizen Stash Cannabis Corp. is headquartered in Mission, Canada.",0,0,0
PTPI,Petros Pharmaceuticals Inc,Common Stock,3.094,$29.69M,https://finance.yahoo.com/quote/PTPI/profile?p=PTPI,"Petros Pharmaceuticals, Inc. engages in identifying, acquiring, developing, and commercializing therapeutics for men's health issues in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company develops H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. It also offers prescription medication, such as Stendra for the treatment of male erectile dysfunction; and vacuum erection devices. Petros Pharmaceuticals, Inc. is based in New York, New York.",0,0,0
CYTR,CytRx Corp,Common Stock,0.7897,$30.01M,https://finance.yahoo.com/quote/CYTR/profile?p=CYTR,"CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed cytotoxin agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides ACDx, an albumin companion diagnostic product to identify patients with cancer who are most likely to benefit from treatment with these drug candidates. CytRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.",0,0,0
SNPX,Synaptogenix,Common Stock,9.1,$30.48M,https://finance.yahoo.com/quote/SNPX/profile?p=SNPX,"Synaptogenix, Inc. operates as a biopharmaceutical company. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and niemann-pick type C disease. It has licensing agreements with Stanford University; Icahn School of Medicine; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is based in New York, New York.",0,0,1
CPHI,China Pharma Holdings Inc,Common Stock,0.7201,$30.72M,https://finance.yahoo.com/quote/CPHI/profile?p=CPHI,"China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.",0,0,0
PRFX,Painreform Ltd,Common Stock,2.88,$30.89M,https://finance.yahoo.com/quote/PRFX/profile?p=PRFX,"PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.",1,0,0
EMHTF,Emerald Health Therapeutics Inc,Common Stock,0.1456,$30.93M,https://finance.yahoo.com/quote/EMHTF/profile?p=EMHTF,"Emerald Health Therapeutics, Inc., together with its subsidiaries, engages in the production and sale of medical cannabis for medical purpose in Canada. It offers dried cannabis strains, pre-rolls, ingestible extracts, and cannabis oil products to its medical patients. The company distributes its medical products through licensed wholesale pharmacies and to licensed wholesale clients. It also exports medical cannabis products to licensed wholesale purchasers in Europe. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.",0,0,0
CVALF,Covalon Technologies Ltd,Common Stock,1.2,$30.98M,https://finance.yahoo.com/quote/CVALF/profile?p=CVALF,"Covalon Technologies Ltd. researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, the United Kingdom, Europe, the Middle East, Asia, Latin America, and internationally. The company has five proprietary platform technologies, including collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; antimicrobial silicone adhesive platform that is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity; medical coating platform, a proprietary process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device; aquaguard moisture barrier technology, an impermeable moisture barrier that allows the clinician or patient to cover wounds, dressings, and intravenous sites to keep them dry; and covaguard antimicrobial sanitizing technology that incorporates Benzalkonium Chloride into a lipid delivery system to surfaces and skin to kill viruses and bacteria. Its products include wound care dressings; surgical and peri-operative products; infection management products; moisture barriers; and antimicrobial sanitizers under the Covalon brand name. The company sells its products through third-party distribution networks and company's direct sales force. It serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. The company is headquartered in Mississauga, Canada.",0,0,0
ATXI,Avenue Therapeutics Inc,Common Stock,1.89,$30.98M,https://finance.yahoo.com/quote/ATXI/profile?p=ATXI,"Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.",1,1,0
PTIX,Protagenic Therapeutics Inc,Common Stock,2.26,$31.05M,https://finance.yahoo.com/quote/PTIX/profile?p=PTIX,"Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.",0,0,0
ADTX,Aditxt Inc,Common Stock,2.17,$31.42M,https://finance.yahoo.com/quote/ADTX/profile?p=ADTX,"ADiTx Therapeutics, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. ADiTx Therapeutics has a license agreement with Loma Linda University and Leland Stanford Junior University. ADiTx Therapeutics, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.",0,0,0
HOTH,Hoth Therapeutics Inc,Common Stock,1.36,$31.75M,https://finance.yahoo.com/quote/HOTH/profile?p=HOTH,"Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. Its pipeline portfolio includes HT-001, a topical formulation for the treatment of mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy; HT-002 to treat illness associated with SARS-CoV-2 infection; HT-003D for the topical treatment in acne and psoriasis applications; HT-003IB to treat inflammatory bowel diseases; HT-004 for the treatment of asthma, atopic dermatitis, and other allergic diseases; HT-005 Z-PODS to treat cutaneous lupus erythematosus; HT-006 for treatment of multiple bacterial pathogens. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; and the University of Cincinnati. It also has a partnership agreement with ZylÃ¶ Therapeutics Inc. co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life; and research collaboration agreement with Weill Cornell Medicine to continue the advancement of HT-003 for acne treatment research. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.",0,0,0
NLSP,NLS Pharmaceutics Ltd,Common Stock,2.78,$32.46M,https://finance.yahoo.com/quote/NLSP/profile?p=NLSP,"NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is based in Stans, Switzerland.",0,0,0
DLTNF,Delta 9 Cannabis Inc,Common Stock,0.3298,$33.31M,https://finance.yahoo.com/quote/DLTNF/profile?p=DLTNF,"Delta 9 Cannabis Inc. operates as an integrated cannabis company. The company, through its subsidiary, Delta 9 Bio-Tech Inc., engages in the cultivation, processing, extraction, wholesale distribution, retail, and sale of medical and recreational cannabis and related merchandise and devices. As of April 14, 2021, it owned and operated 12 retail stores under the Delta 9 Cannabis Store brand. Delta 9 Cannabis Inc. was founded in 2012 and is headquartered in Winnipeg, Canada.",0,0,0
HSTO,Histogen Inc,Common Stock,0.8273,$33.71M,https://finance.yahoo.com/quote/HSTO/profile?p=HSTO,"Histogen Inc., a clinical-stage therapeutics company, focuses on developing therapeutics based upon the products of fibroblast cells grown under simulated embryonic conditions. It offers HST-001, a hair stimulating complex that is in Phase 1b/2a clinical trial for the treatment of androgenic alopecia (hair loss); HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; and Emricasan, an orally active pan-caspase inhibitor that is in Phase 1 clinical trial for the treatment of COVID-19. The company's pre-clinical programs include HST-004, a cell conditioned media (CCM) solution to treat spinal disc repair; and HST-002, a human-derived collagen and extracellular matrix dermal filler for the treatment of facial folds and wrinkles. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.",0,0,0
ACER,Acer Therapeutics Inc,Common Stock,2.4,$33.77M,https://finance.yahoo.com/quote/ACER/profile?p=ACER,"Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 2013 and is headquartered in Newton, Massachusetts.",0,0,0
NDVAF,Indiva Ltd,Common Stock,0.26725,$33.88M,https://finance.yahoo.com/quote/NDVAF/profile?p=NDVAF,"Indiva Limited operates as a licensed producer of cannabis products in Canada. It creates premium pre-rolls, flower, capsules, and edible products, as well as provides production and manufacturing services to peer entities. The company produces and distributes the Bhang Chocolate, Wana Sour Gummies, Ruby Cannabis Sugar, Sapphire Cannabis Salt, Artisan Batch, and other powered by INDIVA products through license agreements and partnerships. Indiva Limited is based in Ottawa, Canada.",0,0,0
PBLA,Panbela Therapeutics Inc,Common Stock,2.85,$34.24M,https://finance.yahoo.com/quote/PBLA/profile?p=PBLA,"Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase 1a/1b clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was founded in 2011 and is based in Waconia, Minnesota.",0,0,0
LVCNF,Leviathan Natural Products Inc,Common Stock,0.4053,$34.35M,https://finance.yahoo.com/quote/LVCNF/profile?p=LVCNF,"Leviathan Natural Products Inc. engages in cultivating, processing, and distributing of cannabis and hemp products in Canada, the United States, and Colombia. The company was formerly known as Leviathan Cannabis Group Inc. and changed its name to Leviathan Natural Products Inc. in July 2020. Leviathan Natural Products Inc. is headquartered in Toronto, Canada.",0,0,0
LEXX,Lexaria Bioscience Corp,Common Stock,6.42,$34.40M,https://finance.yahoo.com/quote/LEXX/profile?p=LEXX,"Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.",0,0,0
TMBR,Timber Pharmaceuticals Inc,Common Stock,0.9564,$34.49M,https://finance.yahoo.com/quote/TMBR/profile?p=TMBR,"Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical dermatology company, focused on the development and commercialization of treatments for orphan dermatologic diseases. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.",0,0,0
PKTX,Protokinetix Inc,Common Stock,0.1255,$34.74M,https://finance.yahoo.com/quote/PKTX/profile?p=PKTX,"ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in health care solutions. It develops AAGP to treat dry eye diseases. The company has a collaboration research agreement with the University of British Columbia. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Marietta, Ohio.",0,0,0
EVOK,Evoke Pharma Inc,Common Stock,1.12,$34.96M,https://finance.yahoo.com/quote/EVOK/profile?p=EVOK,"Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.",1,1,0
VVCIF,VIVO Cannabis Inc,Common Stock,0.0945,$35.35M,https://finance.yahoo.com/quote/VVCIF/profile?p=VVCIF,"VIVO Cannabis Inc. cultivates, produces, and sells cannabis products for the medical and adult-use markets in Canada, Germany, and Australia. The company offers dried cannabis flower products, pre-rolls and cannabis oils, and other cannabis-derived products; and cannabis-infused chocolates, vapes, kief, live rosin, bubble hash, brick hash, and shatter and wax solvent extracts under the Canna Farms, Beacon Medical, Fireside, Fireside-X, Lumina, and Canadian Bud Collection brands. The company also operates a network of medical cannabis clinics under the Harvest Medicine name. It serves customers through direct and retail sale; and HMED Connect telemedicine platform, an online medical cannabis platform. The company is headquartered in Napanee, Canada.",0,0,0
APLIF,Appili Therapeutics Inc,Common Stock,0.6036,$35.61M,https://finance.yahoo.com/quote/APLIF/profile?p=APLIF,"Appili Therapeutics Inc., a biopharmaceutical company, acquires, develops, and commercializes novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1501, a taste-masked oral liquid suspension formulation of an antibiotic, metronidazole; ATI-1503 that develops a class of gram-negative targeting antibiotics; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was founded in 2015 and is headquartered in Halifax, Canada.",0,0,0
LIXT,Lixte Biotechnology Holdings Inc,Common Stock,2.79,$35.93M,https://finance.yahoo.com/quote/LIXT/profile?p=LIXT,"Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases; and LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; pharmacologic study with the National Cancer Institute; and clinical research support agreement with City of Hope National Medical Center to carry out a Phase 1b clinical trial of its LB-100, a protein phosphatase inhibitor for small cell lung cancer. The company was incorporated in 2005 and is based in East Setauket, New York.",0,0,0
BUDZ,WEED Inc,Common Stock,0.3,$36.03M,https://finance.yahoo.com/quote/BUDZ/profile?p=BUDZ,"WEED, Inc., an early stage holding company, focuses on the development and application of cannabis-derived compounds for the treatment of human diseases primarily in the United States. The company was formerly known as United Mines, Inc. and changed its name to WEED, Inc. in February 2015. WEED, Inc. was incorporated in 1999 and is headquartered in Tucson, Arizona.",0,0,0
YTEN,Yield10 Bioscience Inc,Common Stock,7.68,$36.22M,https://finance.yahoo.com/quote/YTEN/profile?p=YTEN,"Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing technologies to enable step-change increases in crop yield in the United States and Canada. The company, through its Trait Factory, is involved in developing oilseed Camelina to produce proprietary products; and high value seed traits for the agriculture and food industries. Yield10 Bioscience, Inc. has license agreements with GDM Seeds; J. R. Simplot; Forage Genetics International, LLC; and Bayer AG. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was founded in 1992 and is headquartered in Woburn, Massachusetts.",0,0,0
SLRX,Salarius Pharmaceuticals Inc,Common Stock,0.87,$36.30M,https://finance.yahoo.com/quote/SLRX/profile?p=SLRX,"Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.",0,0,0
CURR,Cure Pharmaceutical Holding Corp,Common Stock,0.56,$37.15M,https://finance.yahoo.com/quote/CURR/profile?p=CURR,"CURE Pharmaceutical Holding Corp., together with its subsidiaries, operates as a technology focused vertically integrated drug delivery and product development company in the pharmaceutical, and health and wellness markets. It focuses on the development and manufacturing of drug formulation and drug delivery technologies in novel dosage forms to enhance drug safety, efficacy, and patient adherence. The company operates through two business segments: Cure and Sera Labs. Its pharmaceutical drug programs include CUREfilm Blue, a sildenafil oral thin film (OTF) for the treatment of erectile dysfunction; cannabinoid products with optimized pharmacokinetic profiles using microCURE and CUREfilm technology; CUREfilm Anti-Viral, an orally bio-available anti-viral of an existing therapeutic leveraging existing pre-clinical/clinical safety and toxicity data; and CUREfilm Central Nervous System, a novel dosage form to treat mental health disorders, such as depression, PTSD, addiction disorders, obsessive compulsive disorders, and anxiety. The company also sells various wellness products under its distribution partners' brands. In addition, it is developing 50,000IU and Vitamin D3 OTF for oral administration. The company has a licensing agreement with Canopy Growth Corporation. CURE Pharmaceutical Holding Corp. was founded in 2011 and is based in Oxnard, California.",0,0,0
RGRX,RegeneRx Biopharmaceuticals Inc,Common Stock,0.29,$37.37M,https://finance.yahoo.com/quote/RGRX/profile?p=RGRX,"RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.",0,0,0
ACOR,Acorda Therapeutics Inc,Common Stock,3.89,$37.58M,https://finance.yahoo.com/quote/ACOR/profile?p=ACOR,"Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.",0,0,0
BMMJ,Body and Mind Inc,Common Stock,0.34495,$38.03M,https://finance.yahoo.com/quote/BMMJ/profile?p=BMMJ,"Body and Mind Inc. cultivates, produces, processes, distributes, and retails medical and recreational cannabis in Nevada, California, Arkansas, and Ohio. The company offers packaged and grinded flower buds; concentrates; disposable pen vaporizers; distillate oil cartridges; and distillate infused edible products. It produces and sells cannabis flowers, oil extracts, and edibles under the Body and Mind brand name. The company also operates ShowGrow San Diego dispensary; and manages ShowGrow Long Beach dispensary. In addition, it is involved in the production of marijuana extract products, such as distillate oils, ice waxes, dry sifts, shatters, edibles, and topicals. The company was formerly known as Deploy Technologies Inc. and changed its name to Body and Mind Inc. in November 2017. Body and Mind Inc. was founded in 1998 and is headquartered in Vancouver, Canada.",0,0,0
SNGX,Soligenix Inc,Common Stock,0.997,$39.28M,https://finance.yahoo.com/quote/SNGX/profile?p=SNGX,"Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which has completed Phase I/II clinical trial for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease and SGX201 for acute radiation enteritis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.",1,1,0
ENVB,Enveric Biosciences Inc,Common Stock,1.95,$39.57M,https://finance.yahoo.com/quote/ENVB/profile?p=ENVB,"Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. It has a pipeline of development programs for radiodermatitis, glioblastoma multiforme, pruritus, rashes, and dry skin and chemotherapy-induced neuropathy. The company is headquartered in Naples, Florida.",0,0,0
HBORF,Harborside Inc,Common Stock,1.1993,$40.03M,https://finance.yahoo.com/quote/HBORF/profile?p=HBORF,"Harborside Inc. cultivates, manufactures, distributes, and sells cannabis and cannabis products. The company owns and operates three retail dispensaries in California and Oregon; and a dispensary under a management services agreement. It also operates a 47 acres of cultivation facility located in Salinas, California. The company sells its products under the Harborside, Harborside Farms, Harborside Farms Reserve, and KEY brands. The company was founded in 2006 and is headquartered in Oakland, California.",0,0,0
ACUR,Acura Pharmaceuticals Inc,Common Stock,0.575,$40.36M,https://finance.yahoo.com/quote/ACUR/profile?p=ACUR,"Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.",0,0,0
TRVI,Trevi Therapeutics Inc,Common Stock,1.888,$40.55M,https://finance.yahoo.com/quote/TRVI/profile?p=TRVI,"Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation; and Rutgers to develop and commercialize products incorporating nalbuphine for any human or animal use. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.",0,1,0
ADIL,Adial Pharmaceuticals Inc,Common Stock,2.4,$40.78M,https://finance.yahoo.com/quote/ADIL/profile?p=ADIL,"Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.",1,0,0
ENZN,Enzon Pharmaceuticals Inc,Common Stock,0.505,$40.81M,https://finance.yahoo.com/quote/ENZN/profile?p=ENZN,"Enzon Pharmaceuticals, Inc., together with its subsidiaries, licenses drug products. Its marketed drug products include PegIntron and Sylatron. The company was incorporated in 1981 and is headquartered in Cranford, New Jersey.",0,0,0
IGXT,IntelGenx Technologies Corp,Common Stock,0.40886,$40.91M,https://finance.yahoo.com/quote/IGXT/profile?p=IGXT,"IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.",0,0,1
KHRNF,Khiron Life Sciences Corp,Common Stock,0.25538,$41.89M,https://finance.yahoo.com/quote/KHRNF/profile?p=KHRNF,"Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America, North America, and Europe. It operates through three segments: Medical Cannabis Products, Health Services, and Wellbeing Products. The company focuses on the cultivation, production, distribution, and export of tetrahydrocannabinol and CBD (cannabidiol) medical cannabis. It also operates a network of health centers and satellite clinics under the ILANS and Zerenia brands; develops CBD-based cosmeceutical products under the Kuida brand name; and operates Zerenia clinic in Medellin and Peru. Khiron Life Sciences Corp. is based in Vancouver, Canada.",0,0,0
UNCY,Unicycive Therapeutics Inc,Common Stock,2.97,$42.36M,https://finance.yahoo.com/quote/UNCY/profile?p=UNCY,"Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.",0,0,0
ABIO,ARCA biopharma Inc,Common Stock,3.04,$42.94M,https://finance.yahoo.com/quote/ABIO/profile?p=ABIO,"ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). The company also engages in the development of AB171, a thiol-containing derivative isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.",0,1,0
TLGT,Teligent Inc,Common Stock,0.49,$43.61M,https://finance.yahoo.com/quote/TLGT/profile?p=TLGT,"Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The company's topical semi-solid and liquid products are used in various applications that range from cosmetics and cosmeceuticals; and the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. It sells its products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was incorporated in 1977 and is based in Buena, New Jersey.",0,0,0
CNSP,CNS Pharmaceuticals Inc,Common Stock,1.72,$43.62M,https://finance.yahoo.com/quote/CNSP/profile?p=CNSP,"CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based in Houston, Texas.",0,0,0
KRBP,Kiromic BioPharma Inc,Common Stock,3.26,$44.01M,https://finance.yahoo.com/quote/KRBP/profile?p=KRBP,"Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. and Leon Office (H.K.). The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.",0,0,0
BPTH,Bio-Path Holdings Inc,Common Stock,6.52,$44.27M,https://finance.yahoo.com/quote/BPTH/profile?p=BPTH,"Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. The company is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.",0,1,0
TENX,Tenax Therapeutics Inc,Common Stock,1.78,$45.11M,https://finance.yahoo.com/quote/TENX/profile?p=TENX,"Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company develops levosimendan, which completed a phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction; and Imatinib, a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.",0,1,0
VIRI,Virios Therapeutics Inc,Common Stock,5.58,$45.73M,https://finance.yahoo.com/quote/VIRI/profile?p=VIRI,"Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was incorporated in 2012 and is headquartered in Alpharetta, Georgia.",0,0,0
CYCC,Cyclacel Pharmaceuticals Inc,Common Stock,5.08,$46.82M,https://finance.yahoo.com/quote/CYCC/profile?p=CYCC,"Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.",0,0,0
WINT,Windtree Therapeutics Inc,Common Stock,1.88,$47.00M,https://finance.yahoo.com/quote/WINT/profile?p=WINT,"Windtree Therapeutics, Inc., a clinical-stage biotechnology and medical device company, focuses on the development of therapeutics for the treatment of acute pulmonary and cardiovascular diseases. Its lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company has a collaboration with University of Milan-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. operates as a subsidiary of Lee's Pharmaceutical Holdings Limited.",0,1,0
PULM,Pulmatrix Inc,Common Stock,0.8433,$47.31M,https://finance.yahoo.com/quote/PULM/profile?p=PULM,"Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trials for the prevention and treatment of fungal infections and allergic/hypersensitivity reactions to fungus in patients with severe lung diseases comprising asthma, cystic fibrosis, and allergic bronchopulmonary aspergillosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with lung cancer and chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.",0,1,0
ARFXF,ProMIS Neurosciences Inc,Common Stock,0.1612,$48.80M,https://finance.yahoo.com/quote/ARFXF/profile?p=ARFXF,"ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platformÂProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (AÃO); and PMN330, a monoclonal antibody targeting toxic prion-like forms of AÃO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company has a collaboration with BC Neuroimmunology to develop and commercialize proprietary diagnostic assays; and BC Neuroimmunology to develop and offer blood-based diagnostic tests for Alzheimer's diseases. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.",0,0,1
ACXP,Acurx Pharmaceuticals Inc,Common Stock,5.2,$48.95M,https://finance.yahoo.com/quote/ACXP/profile?p=ACXP,"Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.",0,1,0
JUVAF,Juva Life Inc,Common Stock,0.37784,$49.05M,https://finance.yahoo.com/quote/JUVAF/profile?p=JUVAF,"Juva Life Inc. engages in the cultivation, research, manufacturing, distribution, and sale of medical and recreational cannabis products in California. The company was founded in 2018 and is headquartered in Vancouver, Canada.",0,0,0
QLGN,Qualigen Therapeutics Inc,Common Stock,1.75,$49.30M,https://finance.yahoo.com/quote/QLGN/profile?p=QLGN,"Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.",0,0,0
NAVB,Navidea Biopharmaceuticals Inc,Common Stock,1.7,$49.92M,https://finance.yahoo.com/quote/NAVB/profile?p=NAVB,"Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694 and NAV5001, a neuro-tracer product candidates. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.",0,0,0
ELTP,Elite Pharmaceuticals Inc,Common Stock,0.05,$49.95M,https://finance.yahoo.com/quote/ELTP/profile?p=ELTP,"Elite Pharmaceuticals, Inc. engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Hydromorphone HCl 8mg tablets for pains under the Dilaudid brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Methadone HCl tablets for pains under the Dolophine brand; and Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; and SequestOX, an immediate release Oxycodone with Naltrexone. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. It has a manufacturing and license agreement with Epic Pharma LLC; development and license agreement with SunGen Pharma, LLC; and strategic marketing alliance with Glenmark Pharmaceuticals, Inc. USA, as well as Lannett Company. Inc. The company was founded in 1984 and is headquartered in Northvale, New Jersey.",0,0,0
BXRX,Baudax Bio Inc,Common Stock,0.6203,$49.97M,https://finance.yahoo.com/quote/BXRX/profile?p=BXRX,"Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.",0,1,0
CHALF,Chalice Brands Ltd,Common Stock,0.84,$50.22M,https://finance.yahoo.com/quote/CHALF/profile?p=CHALF,"Chalice Brands Ltd., through its subsidiaries, produces, distributes, and sells cannabis oil and flower products in the United States. The company provides distillate vaporizer cartridges, ethanol extract products, and fruit chew blast products. It offers its products under the Private Stash, Jackpot, Chalice, Golden, RXO, and Elysium Fields brands. The company also engages in the ownership, administration, and leasing of real estate and intellectual properties, and capital equipment, as well as industrial hemp processing activities. In addition, it operates a network of six dispensaries under the Chalice Farms brand; and one dispensary under the Left Coast Connections brand in Oregon, as well as operates as a toll processing and white label service consultant. The company was formerly known as Golden Leaf Holdings Ltd. and changed its name to Chalice Brands Ltd. in May 2021. Chalice Brands Ltd. is based in Toronto, Canada.",0,0,0
KTRA,Kintara Therapeutics Inc,Common Stock,1.58,$50.23M,https://finance.yahoo.com/quote/KTRA/profile?p=KTRA,"Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.",1,1,0
AGE,AgeX Therapeutics Inc,Common Stock,1.37,$50.26M,https://finance.yahoo.com/quote/AGE/profile?p=AGE,"AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; a collaboration with Sernova Corp.; and a research collaboration with The Ohio State University using AgeX's brown adipocyte tissue cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health, and cardiac function. The company was founded in 2017 and is based in Alameda, California.",0,0,0
MRZM,Marizyme Inc,Common Stock,1.4,$50.30M,https://finance.yahoo.com/quote/MRZM/profile?p=MRZM,"Marizyme, Inc., a development stage company, focuses on life science technologies business. It offers DuraGraft, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. The company also develops various products using its Krillase protease-based therapeutic platform, which includes MB101 for complex wounds and burns; MB102 for acute ischemic stroke; MB104 for deep vein thrombosis; and MB105 for dissolving plaque and biofilms on teeth. In addition, it focuses on developing products to mitigate the effects of ischemia reperfusion injury in other grafting and transplantation surgeries, and other indications. The company was formerly known as GBS Enterprises Incorporated. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida.",0,0,0
ASRT,Assertio Holdings Inc,Common Stock,1.19,$50.83M,https://finance.yahoo.com/quote/ASRT/profile?p=ASRT,"Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. The company's pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; moderate to severe ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, an NSAID for relief of mild to moderate acute pain; and SPRIX, an NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.",0,0,0
AZRX,AzurRx BioPharma Inc,Common Stock,0.5628,$51.00M,https://finance.yahoo.com/quote/AZRX/profile?p=AZRX,"AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida.",0,0,0
CPIX,Cumberland Pharmaceuticals Inc,Common Stock,3.39,$51.02M,https://finance.yahoo.com/quote/CPIX/profile?p=CPIX,"Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ injection, for the treatment of certain serious bacterial infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. The company markets and sells its products through sales representatives and district managers. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.",0,1,0
IDRA,Idera Pharmaceuticals Inc,Common Stock,1.03,$51.03M,https://finance.yahoo.com/quote/IDRA/profile?p=IDRA,"Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.",0,0,0
ASPCF,Acerus Pharmaceuticals Corp,Common Stock,0.0334,$51.36M,https://finance.yahoo.com/quote/ASPCF/profile?p=ASPCF,"Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; and Tefina, a clinical stage product for women with female sexual dysfunction. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. Acerus Pharmaceuticals Corporation sells products through its salesforce in the United States; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.",0,0,0
RGLS,Regulus Therapeutics Inc,Common Stock,0.7184,$52.22M,https://finance.yahoo.com/quote/RGLS/profile?p=RGLS,"Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase 1 development for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 glioblastoma multiforme program; and Hepatitis B virus, non-alcoholic steatohepatitis, and cell therapies programs. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.",0,0,0
BBI,Brickell Biotech Inc,Common Stock,0.6867,$52.73M,https://finance.yahoo.com/quote/BBI/profile?p=BBI,"Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. It has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.",1,0,0
DFFN,Diffusion Pharmaceuticals Inc,Common Stock,0.5531,$53.29M,https://finance.yahoo.com/quote/DFFN/profile?p=DFFN,"Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company is also developing DFN-529, a phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway inhibitor. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.",0,0,0
NBRV,Nabriva Therapeutics plc,Common Stock,1.08,$53.36M,https://finance.yahoo.com/quote/NBRV/profile?p=NBRV,"Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI). It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.",0,0,0
OCUP,Ocuphire Pharma Inc,Common Stock,4.44,$53.65M,https://finance.yahoo.com/quote/OCUP/profile?p=OCUP,"Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.",1,1,0
CYTH,Cyclo Therapeutics Inc,Common Stock,8.5499,$53.99M,https://finance.yahoo.com/quote/CYTH/profile?p=CYTH,"Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. The company's lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.",0,0,0
WDDMF,Entourage Health Corp,Common Stock,0.2148,$54.36M,https://finance.yahoo.com/quote/WDDMF/profile?p=WDDMF,"WeedMD Inc. produces, distributes, and sells medical-grade cannabis in Canada. It offers dried cannabis, cannabis plants and seeds, cannabis oil, edibles, extracts and topicals, and others, as well as cannabis flower products. The company sells its products directly to medical patients and strategic relationships across the seniors' market, as well as through supply agreements with Shoppers Drug Mart and six provincial distribution agencies under the Color Cannabis, Saturday, Starseed, and WeedMD brand names. WeedMD Inc. is headquartered in Aylmer, Canada.",0,0,0
BCDA,BioCardia Inc,Common Stock,3.45,$54.75M,https://finance.yahoo.com/quote/BCDA/profile?p=BCDA,"BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.",0,0,0
IKT,Inhibikase Therapeutics Inc,Common Stock,2.27,$54.79M,https://finance.yahoo.com/quote/IKT/profile?p=IKT,"Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.",0,0,0
NGENF,Nervgen Pharma Corp,Common Stock,1.36,$54.80M,https://finance.yahoo.com/quote/NGENF/profile?p=NGENF,"NervGen Pharma Corp., a biotech company, discovers and develops treatments for patients suffering from medical conditions related to nerve damage. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.",0,0,1
BIOC,Biocept Inc,Common Stock,4.16,$54.95M,https://finance.yahoo.com/quote/BIOC/profile?p=BIOC,"Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. It has a partnership with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.",0,0,0
ARDS,Aridis Pharmaceuticals Inc,Common Stock,5.04,$55.04M,https://finance.yahoo.com/quote/ARDS/profile?p=ARDS,"Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.",1,1,0
SKYE,Skye Bioscience Inc,Common Stock,0.15,$55.61M,https://finance.yahoo.com/quote/SKYE/profile?p=SKYE,"Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based therapeutics for the treatment of infectious diseases. The company's lead product candidate is THCVHS, which is in preclinical trials for the treatment of glaucoma. It is also developing CBDVHS that is in preclinical trials to treat various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy; and Cannabinoid Cocktail for the treatment of anti-infective diseases. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.",0,0,0
UPC,Universe Pharmaceuticals Inc,Common Stock,2.4,$55.90M,https://finance.yahoo.com/quote/UPC/profile?p=UPC,"Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief for common chronic health conditions in the elderly for the physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'an, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.",0,0,0
HERTF,Heritage Cannabis Holdings Corp,Common Stock,0.07,$56.38M,https://finance.yahoo.com/quote/HERTF/profile?p=HERTF,"Heritage Cannabis Holdings Corp., through its subsidiaries, operates as a cannabinoid company that focuses on the production and sale of medical and recreational hemp-based and cannabis-based products and services in Canada and the United States. It offers extraction services; and focuses on processing, manufacturing, and distributing medical cannabis products and cannabis oils. It provides integrative approach to cannabinoid therapy for healthcare consumers and healthcare practitioners. The company was formerly known as Umbral Energy Corp. and changed its name to Heritage Cannabis Holdings Corp. in January 2018. Heritage Cannabis Holdings Corp. was incorporated in 2007 and is headquartered in Toronto, Canada.",0,0,0
NNVC,NanoViricides Inc,Common Stock,4.57,$56.60M,https://finance.yahoo.com/quote/NNVC/profile?p=NNVC,"NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. Its products pipeline includes HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of all types of Dengue viruses; and HIVCide that is an escape-resistant anti-HIV nanoviricide. In addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.",0,0,0
AUSAF,Australis Capital Inc,Common Stock,0.2097,$56.61M,https://finance.yahoo.com/quote/AUSAF/profile?p=AUSAF,"Australis Capital Inc. is a venture capital specializing in early-stage but not limited to equity positions and/or debt in both public and private companies, financings in exchange for royalties or other distribution streams, and control share acquisitions and buyouts. It seeks to identify and invest in United States and abroad in cannabis and real estate assets. Australis Capital Inc. is based in Las Vegas, Nevada and additional offices in Vancouver, Canada.",0,0,0
CLRB,Cellectar Biosciences Inc,Common Stock,1.12,$56.94M,https://finance.yahoo.com/quote/CLRB/profile?p=CLRB,"Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in preclinical stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; and Orano Med to develop CLR 12120 Series. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.",0,1,0
HUGE,FSD Pharma Inc,Common Stock,1.71,$58.67M,https://finance.yahoo.com/quote/HUGE/profile?p=HUGE,"FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD 201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also develops drugs for the treatment of pain, inflammation, and neurological disorders. It has license agreements with Epitech Group SpA.; and with Innovet Italia S.R.L. to develop veterinary drugs for the treatment of gastro-intestinal diseases in dogs and cats. The company was founded in 1998 and is headquartered in Toronto, Canada.",0,1,0
CLCS,Cell Source Inc,Common Stock,1.8,$58.79M,https://finance.yahoo.com/quote/CLCS/profile?p=CLCS,"Cell Source, Inc., a biotechnology company, develops cell therapy treatments. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, such as treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. The company was founded in 2011 and is headquartered in New York, New York.",0,0,0
ADXS,Advaxis Inc,Common Stock,0.43,$60.03M,https://finance.yahoo.com/quote/ADXS/profile?p=ADXS,"Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.",0,1,0
ALIM,Alimera Sciences Inc,Common Stock,8.62,$60.08M,https://finance.yahoo.com/quote/ALIM/profile?p=ALIM,"Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.",0,0,0
GLMD,Galmed Pharmaceuticals Ltd,Common Stock,2.46,$60.45M,https://finance.yahoo.com/quote/GLMD/profile?p=GLMD,"Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.",1,1,0
MBXBF,Microbix Biosystems Inc,Common Stock,0.49665,$60.84M,https://finance.yahoo.com/quote/MBXBF/profile?p=MBXBF,"Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.",0,0,0
OTLC,Oncotelic Therapeutics Inc,Common Stock,0.1739,$61.41M,https://finance.yahoo.com/quote/OTLC/profile?p=OTLC,"Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.",1,0,0
FLOOF,Flower One Holdings Inc,Common Stock,0.1486,$61.42M,https://finance.yahoo.com/quote/FLOOF/profile?p=FLOOF,"Flower One Holdings Inc., a cannabis cultivator and producer, engages in the cultivation and production medical and recreational cannabis. It owns and operates 400,000 square foot greenhouse for cannabis cultivation and 55,000 square foot cannabis production facility in Nevada; and 25,000 square-foot indoor cultivation and a commercial kitchen in Las Vegas. The company cultivates, processes, produces, and packages dry flower, pre-rolls, cannabis oils, distillates, concentrates, edibles, topicals, and infused products; and leases a warehouse in North Las Vegas. It sells its products directly to dispensaries, as well as engages in the contract cultivation, production, and packaging consumer cannabis brands. The company based in Toronto, Canada.",0,0,0
DMAC,DiaMedica Therapeutics Inc,Common Stock,3.46,$61.43M,https://finance.yahoo.com/quote/DMAC/profile?p=DMAC,"DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.",0,1,0
STMH,Stem Holdings Inc,Common Stock,0.2864,$61.70M,https://finance.yahoo.com/quote/STMH/profile?p=STMH,"Stem Holdings, Inc., together with its subsidiaries, operates as a vertically integrated cannabis operating company. It is involved in manufacture, possession, use, sale, distribution, and branding of cannabis and cannabis-infused products under the laws of the states of Oregon, Nevada, California, Massachusetts, and Oklahoma. As of December 30, 2020, the company had ownership interests in 22 state issued cannabis and hemp licenses, including 10 licenses for cannabis cultivation; 4 licenses for cannabis processing; 1 license for cannabis wholesale distribution; 1 license for hemp production and processing; 5 cannabis dispensary licenses; and 1 license that permits both dispensary and cultivation activities. Stem Holdings, Inc. was founded in 2016 and is headquartered in Boca Raton, Florida.",0,0,0
HCANF,Halo Collective Inc,Common Stock,0.034,$62.25M,https://finance.yahoo.com/quote/HCANF/profile?p=HCANF,"Halo Collective Inc. operates as a cannabis cultivation, manufacturing, and distribution company that grows, extracts, and processes cannabis flower, oils, and concentrates in the United States. The company also offers edible products, including single piece chews and a syrup-based drink in California and, Oregon. In addition, it markets branded and private label products. The company sells its cannabis products principally to dispensaries under Hush, Mojave, and Exhale brands. It serves licensed retailers and wholesalers. Halo Collective Inc. has a strategic partnership with High Tide Inc; and with OG DNA Genetics Inc to develop genetics in Oregon. The company was formerly known as Halo Labs Inc. and changed its name to Halo Collective Inc. in January 2021. Halo Collective Inc. was founded in 2016 and is based in Toronto, Canada.",0,0,0
RVPH,Reviva Pharmaceuticals Holdings Inc,Common Stock,3.67,$62.55M,https://finance.yahoo.com/quote/RVPH/profile?p=RVPH,"Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 that has completed Phase II clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials for treating bipolar disorder, major depressive disorder, behavioral and psychotic symptoms, dementia or Alzheimer's disease, parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis; and RP1208 that has completed pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.",0,1,1
LUMO,Lumos Pharma Inc,Common Stock,7.59,$63.34M,https://finance.yahoo.com/quote/LUMO/profile?p=LUMO,"Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.",0,1,0
UNRV,Unrivaled Brands Inc,Common Stock,0.27224,$63.38M,https://finance.yahoo.com/quote/UNRV/profile?p=UNRV,"Unrivaled Brands, Inc. cultivates, produces, and retails medical and adult use cannabis products in California, Oregon, and Nevada. It also operates medical marijuana retail and adult use dispensaries, cultivation, and production facilities. The company was formerly known as Terra Tech Corp. and changed its name to Unrivaled Brands, Inc. in July 2021. Unrivaled Brands, Inc. was founded in 2010 and is based in Santa Ana, California.",0,0,0
ALNA,Allena Pharmaceuticals Inc,Common Stock,0.9999,$65.08M,https://finance.yahoo.com/quote/ALNA/profile?p=ALNA,"Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Newton, Massachusetts.",1,0,0
EDSA,Edesa Biotech Inc,Common Stock,5.0,$65.22M,https://finance.yahoo.com/quote/EDSA/profile?p=EDSA,"Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.",1,1,0
ACHV,Achieve Life Sciences Inc,Common Stock,7.33,$65.30M,https://finance.yahoo.com/quote/ACHV/profile?p=ACHV,"Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.",0,0,0
PTE,PolarityTE Inc,Common Stock,0.8678,$65.36M,https://finance.yahoo.com/quote/PTE/profile?p=PTE,"PolarityTE, Inc., a biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates through two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and OsteoTE. PolarityTE, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.",0,0,0
MNPR,Monopar Therapeutics Inc,Common Stock,5.3,$65.55M,https://finance.yahoo.com/quote/MNPR/profile?p=MNPR,"Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, which is in Phase 2 clinical trial; and MNPR-101, a humanized monoclonal antibody for the treatment of advanced cancers and severe COVID-19 that is in preclinical stage. The company has a collaboration Grupo EspaÃ±ol de InvestigaciÃ³n en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. It also has a collaboration agreement with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in multiple types of cancer. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.",0,1,0
VCNX,Vaccinex Inc,Common Stock,2.49,$66.01M,https://finance.yahoo.com/quote/VCNX/profile?p=VCNX,"Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that is in Phase 1 and 2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders; and VX25, a bi-specific molecule based on natural killer T (NKT) vaccine platform for the therapeutic application of NKT cell stimulation for cancer immunotherapy. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.",0,0,1
ONVO,Organovo Holdings Inc,Common Stock,8.16,$66.10M,https://finance.yahoo.com/quote/ONVO/profile?p=ONVO,"Organovo Holdings, Inc., a biotechnology company, develops bioprinted human tissues based on its 3D human tissue platform technology that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases; and NovoTissues liver product using cells from a liver donor and cells from an umbilical cord donor. The company was founded in 2007 and is headquartered in Solana Beach, California.",0,0,0
NRBO,NeuroBo Pharmaceuticals Inc,Common Stock,3.12,$66.19M,https://finance.yahoo.com/quote/NRBO/profile?p=NRBO,"NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trial to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts.",0,1,0
SYN,Synthetic Biologics Inc,Common Stock,0.5116,$66.81M,https://finance.yahoo.com/quote/SYN/profile?p=SYN,"Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat gastrointestinal (GI) diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in GI tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. The company also develops clinical stage products, such as SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.",0,1,0
BCTX,BriaCell Therapeutics Corp,Common Stock,4.93,$67.65M,https://finance.yahoo.com/quote/BCTX/profile?p=BCTX,"BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.",0,0,0
CWBR,Cohbar Inc,Common Stock,1.12,$70.44M,https://finance.yahoo.com/quote/CWBR/profile?p=CWBR,"CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.",0,0,1
OPNT,Opiant Pharmaceuticals Inc,Common Stock,15.035,$70.47M,https://finance.yahoo.com/quote/OPNT/profile?p=OPNT,"Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.",0,0,0
PLX,Protalix Biotherapeutics Inc,Common Stock,1.62,$70.61M,https://finance.yahoo.com/quote/PLX/profile?p=PLX,"Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; FundaÃ§Ã£o Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.",1,1,0
SLNO,Soleno Therapeutics Inc,Common Stock,0.9207,$71.44M,https://finance.yahoo.com/quote/SLNO/profile?p=SLNO,"Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.",1,1,0
LIFE,aTyr Pharma Inc,Common Stock,4.58,$71.49M,https://finance.yahoo.com/quote/LIFE/profile?p=LIFE,"aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product, ATYR1923, is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of various aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.",0,0,0
LOWLF,Lowell Farms Inc,Common Stock,1.21,$71.54M,https://finance.yahoo.com/quote/LOWLF/profile?p=LOWLF,"Lowell Farms Inc. engages in the cultivation, extraction, processing, manufacturing, branding, packaging, and wholesale distribution of cannabis products to retail dispensaries in California. The company provides flowers, concentrates, vape pens, oils, extracts, chocolate edibles, mints, gummies, beverages, tinctures, and pre-rolls under the Lowell Herb Co., Lowell Smokes, Cypress Reserve, Flavor Extracts, Kaizen, House Weed, Moon, Altai, Humble Flower, Original Pot Company, CannaStripe, and Acme Elixirs brands. It also offers manufacturing, extraction, and distribution services to third-party cannabis and cannabis branding companies. The company was formerly known as Indus Holdings, Inc. and changed its name to Lowell Farms Inc. in March 2021. Lowell Farms Inc. is based in Salinas, California.",0,0,0
SCPS,Scopus BioPharma Inc,Common Stock,4.73,$71.56M,https://finance.yahoo.com/quote/SCPS/profile?p=SCPS,"Scopus BioPharma Inc., a biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Its lead development programs are immuno-oncology gene therapy for the treatment of various cancers, which include CO-sTiRNA, a STAT3 inhibitor gene therapy that drives tumor cell growth and anti-tumor immune suppression; and MRI-1867, a cannabinoid-1 receptor inverse agonist and inhibitor of inducible nitric oxide synthase for the treatment of systemic sclerosis. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.",0,0,0
CDTX,Cidara Therapeutics Inc,Common Stock,1.52,$72.44M,https://finance.yahoo.com/quote/CDTX/profile?p=CDTX,"Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel long-acting anti-infectives for the treatment and prevention of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.",0,0,0
TCON,TRACON Pharmaceuticals Inc,Common Stock,3.83,$73.36M,https://finance.yahoo.com/quote/TCON/profile?p=TCON,"TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and age-related macular degeneration and fibrotic diseases in the United States. Its lead clinical stage product include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.",0,1,0
MTCR,Metacrine Inc,Common Stock,2.96,$75.83M,https://finance.yahoo.com/quote/MTCR/profile?p=MTCR,"Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.",0,1,0
ICCC,ImmuCell Corp,Common Stock,10.0849,$75.85M,https://finance.yahoo.com/quote/ICCC/profile?p=ICCC,"ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.",0,0,0
AIKI,Alkido Pharma Inc,Common Stock,0.8834,$76.46M,https://finance.yahoo.com/quote/AIKI/profile?p=AIKI,"AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement with the University of Texas; and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is based in New York, New York.",0,0,0
CBLI,Cleveland BioLabs Inc,Common Stock,4.99,$77.19M,https://finance.yahoo.com/quote/CBLI/profile?p=CBLI,"Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and immuno-oncology. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand; and CBL0137, a small molecule with a multi-targeted mechanism for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, Rusnano, and Everon Biosciences. The company was incorporated in 2003 and is headquartered in Buffalo, New York.",0,0,0
TBPMF,Tetra Bio-Pharma Inc,Common Stock,0.2029,$78.26M,https://finance.yahoo.com/quote/TBPMF/profile?p=TBPMF,"Tetra Bio-Pharma Inc., a development stage biopharmaceutical company, engages in the discovery and development of immunomodulator drugs. It develops ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; Reduvo for chemotherapy-induced nausea and vomiting; PLENITUDE to treat advanced uncontrolled cancer pain; REBORN for the treatment of breakthrough cancer pain and fibromyalgia; and SERENITY to treat cancer cachexia. The company also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. is headquartered in Orleans, Canada.",0,0,0
ONTX,Onconova Therapeutics Inc,Common Stock,5.29,$78.91M,https://finance.yahoo.com/quote/ONTX/profile?p=ONTX,"Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.",0,0,0
INTI,Inhibitor Therapeutics Inc,Common Stock,0.22,$78.97M,https://finance.yahoo.com/quote/INTI/profile?p=INTI,"Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.",0,1,0
NERV,Minerva Neurosciences Inc,Common Stock,1.91,$79.04M,https://finance.yahoo.com/quote/NERV/profile?p=NERV,"Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.",1,1,0
REPH,Recro Pharma Inc,Common Stock,1.79,$79.82M,https://finance.yahoo.com/quote/REPH/profile?p=REPH,"Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Malvern, Pennsylvania.",0,0,0
CLBS,Caladrius Biosciences Inc,Common Stock,1.36,$80.32M,https://finance.yahoo.com/quote/CLBS/profile?p=CLBS,"Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.",0,1,0
CRVS,Corvus Pharmaceuticals Inc,Common Stock,2.18,$80.45M,https://finance.yahoo.com/quote/CRVS/profile?p=CRVS,"Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and activate various immune cells, as Phase III clinical trial of CPI-006 for COVID-19. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/II clinical trial for adenosine, an immune checkpoint. Its preclinical stage products include CPI-182, an antibody to block neutrophil function and migration, and myeloid derived suppressor cells; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.",1,1,0
LPTX,Leap Therapeutics Inc,Common Stock,1.41,$80.56M,https://finance.yahoo.com/quote/LPTX/profile?p=LPTX,"Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.",0,0,0
APVO,Aptevo Therapeutics Inc,Common Stock,19.39,$81.35M,https://finance.yahoo.com/quote/APVO/profile?p=APVO,"Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer; and other pre-clinical development stage therapeutics focused on hematologic and solid tumors. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.",0,0,0
LYRA,Lyra Therapeutics Inc,Common Stock,6.63,$81.65M,https://finance.yahoo.com/quote/LYRA/profile?p=LYRA,"Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.",0,1,0
MACK,Merrimack Pharmaceuticals Inc,Common Stock,6.39,$82.61M,https://finance.yahoo.com/quote/MACK/profile?p=MACK,"Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded in 1993 and is headquartered in Cambridge, Massachusetts.",0,0,0
VYNT,Vyant Bio Inc,Common Stock,2.98,$82.61M,https://finance.yahoo.com/quote/VYNT/profile?p=VYNT,"Vyant Bio, Inc. operates as a biotechnology drug discovery company. The company, through its subsidiary, StemoniX, develops and manufactures at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development. StemoniX, through collaborations with drug discovery organizations, tests compounds in-house, creates cell-based disease models, and operationalizes custom human iPSC-derived disease models for high-throughput screening. The company, through its subsidiary, vivoPharm, offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages by the pharmaceutical industry, biotechnology companies, and academic research centers. vivoPharm specializes in conducting studies to guide drug development, starting from compound libraries and ending with a set of in vitro and in vivo data and reports, as needed for investigational new drug filings. The company is based in Cherry Hill, New Jersey.",0,0,0
RZLT,Rezolute Inc,Common Stock,10.28,$82.89M,https://finance.yahoo.com/quote/RZLT/profile?p=RZLT,"Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.",0,1,0
CANSF,Willow Biosciences Inc,Common Stock,0.69754,$83.21M,https://finance.yahoo.com/quote/CANSF/profile?p=CANSF,"Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical product industries in Canada. The company also produces cannabidiol, cannabigerol, and varin cannabinoids, such as cannabigerovarin, cannabidivarin, and tetrahydrocannabivarin. Willow Biosciences Inc. is headquartered in Calgary, Canada.",0,0,0
DBCCF,Decibel Cannabis Co Inc,Common Stock,0.2447,$83.40M,https://finance.yahoo.com/quote/DBCCF/profile?p=DBCCF,"Decibel Cannabis Company Inc. engages in the cultivation, processing, production, and retail sale of cannabis products in Canada. It offers cannabis flower, cannabis pre-rolls, and cannabis biomass to licensed producers in Canada. The company is also involved in the extraction, processing, and manufacturing of various cannabis derivative products. It offers its products under the Qwest, Qwest Reserve, and Blendcraft by Qwest brands. Decibel Cannabis Company Inc. is headquartered in Calgary, Canada.",0,0,0
ALID,Allied Corp,Common Stock,1.03,$83.52M,https://finance.yahoo.com/quote/ALID/profile?p=ALID,"Allied Corp., a medical cannabis production company, engages in the research, development, and production of cannabinoid health solutions in the United States. It offers hemp derived natural health products, including Liberty, a hemp derived cannabidiol (CBD) tincture; and Tactical Hydration, a CBD infused electrolyte replacement drink under the Tactical Relief brand. The company also provides Hydro Sport, a CBD-infused rehydration drink under the Equilibrium Bio brand; anti-aging cosmetics and topicals infused with CBD under the MaXXa brand; and anti-aging, anti-pain, and anti-inflammation skin care products under the Buds Pure Naturals brand. In addition, it is developing ALID 12, a pharma product, which is in Phase I clinical trial for treating post-traumatic stress disorder in Colombia. The company is headquartered in Kelowna, Canada.",0,0,0
OPGN,OpGen Inc,Common Stock,2.25,$84.19M,https://finance.yahoo.com/quote/OPGN/profile?p=OPGN,"OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen; and QuickFISH and PNA FISH diagnostic test products for the identification of various infectious pathogens, as well as SARS CoV-2 test kits. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics, which combines clinical lab test results with patient and hospital information to provide analytics and insights to enable manage MDROs in the hospital and patient care environment; Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers; and ARES Technology Platform, including ARESdb, which provides next generation sequencing based and artificial intelligence powered, cloud-based bioinformatics solutions to generate AMR profiles, as well as predict antimicrobial susceptibility test results. OpGen, Inc. has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.",0,0,0
ONCS,OncoSec Medical Inc,Common Stock,2.36,$84.25M,https://finance.yahoo.com/quote/ONCS/profile?p=ONCS,"OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 (IL-12) for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and new DNA-encoded therapeutic candidates and tumor indications to treat deep visceral lesions, such as liver, lung, bladder, pancreatic, and other visceral lesions. It has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate enhanced IL-12 DNA-plasmid; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was founded in 2008 and is headquartered in Pennington, New Jersey.",0,1,0
SLGWF,Slang Worldwide Inc,Common Stock,0.1836,$84.60M,https://finance.yahoo.com/quote/SLGWF/profile?p=SLGWF,"SLANG Worldwide Inc. operates as a cannabis consumer packaged goods company worldwide. It owns, licenses, and/or markets 11 brands which serve flower, inhalable concentrates, and ingestibles, including edibles and pressed pills. The company was formerly known as Fire Cannabis Inc. and changed its name to SLANG Worldwide Inc. in November 2018. SLANG Worldwide Inc. was incorporated in 2017 and is headquartered in Toronto, Canada.",0,0,0
ARAV,Aravive Inc,Common Stock,4.34,$85.13M,https://finance.yahoo.com/quote/ARAV/profile?p=ARAV,"Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain AVB-500 as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.",0,0,0
LMNL,Liminal BioSciences Inc,Common Stock,2.93,$85.34M,https://finance.yahoo.com/quote/LMNL/profile?p=LMNL,"Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel small molecule drug candidates for the treatment of patients suffering from respiratory fibrotic diseases and other fibrotic or inflammatory diseases that have high unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma-Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050), which is in Phase 1 for the treatment of idiopathic pulmonary fibrosis and respiratory diseases. The Plasma-Derived Therapeutics segment focused on the development of its plasma-derived product candidate Ryplazim, a purified glu-plasminogen derived from human plasma that acts as a plasminogen replacement therapy for patients deficient in plasminogen protein. The company operates in Canada, the United Kingdom, and the United States. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.",0,0,0
GRYN,Green Hygienics Holdings Inc,Common Stock,1.9,$85.60M,https://finance.yahoo.com/quote/GRYN/profile?p=GRYN,"Green Hygienics Holdings, Inc., a development stage company, intends to cultivate and process industrial hemp for extracting cannabidiol. The company was formerly known as Takedown Entertainment Inc. and changed its name to Green Hygienics Holdings Inc. in July 2012. Green Hygienics Holdings Inc. was founded in 2008 and is based in Poway, California.",0,0,0
GRAY,Graybug Vision Inc,Common Stock,4.24,$86.54M,https://finance.yahoo.com/quote/GRAY/profile?p=GRAY,"Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.",0,1,0
MEDIF,Medipharm Labs Corp,Common Stock,0.33736,$86.71M,https://finance.yahoo.com/quote/MEDIF/profile?p=MEDIF,"MediPharm Labs Corp., together with its subsidiaries, produces and sells pharmaceutical-grade cannabis oil and concentrates, and advance derivative products in Canada and Australia. It formulates, processes, packages, and distributes cannabis extracts and cannabinoid-based products. The company was founded in 2015 and is headquartered in Barrie, Canada.",0,0,0
TARA,Protara Therapeutics Inc,Common Stock,8.11,$87.02M,https://finance.yahoo.com/quote/TARA/profile?p=TARA,"Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.",0,0,0
AZYO,Aziyo Biologics Inc,Common Stock,8.14,$87.45M,https://finance.yahoo.com/quote/AZYO/profile?p=AZYO,"Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device; and cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. The company also provides FiberCel, ViBone, and OsterGro V that are designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. In addition, it offers contract manufacturing services for various products to corporate customers. The company sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. Aziyo Biologics, Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.",0,0,0
APM,Aptorum Group Ltd,Common Stock,2.615,$87.93M,https://finance.yahoo.com/quote/APM/profile?p=APM,"Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.",0,0,0
YMTX,Yumanity Therapeutics Inc,Common Stock,9.13,$88.15M,https://finance.yahoo.com/quote/YMTX/profile?p=YMTX,"Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. It focuses on discovering disease-modifying therapies to treat Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's diseases. Its lead program is YTX-7739, a novel small molecule for the treatment of Parkinson's disease and related disorders of a-synuclein that is in Phase I clinical trial. The company is also developing YTX-9184 for the treatment of dementia with Lewy bodies. Yumanity Therapeutics Inc. has a strategic research and development collaboration agreement with Merck Sharp & Dohme Corp. The company is headquartered in Boston, Massachusetts.",0,0,1
ELDN,Eledon Pharmaceuticals Inc,Common Stock,6.24,$88.42M,https://finance.yahoo.com/quote/ELDN/profile?p=ELDN,"Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.",0,1,0
CRTPF,Cardiol Therapeutics Inc,Common Stock,2.07,$89.37M,https://finance.yahoo.com/quote/CRTPF/profile?p=CRTPF,"Cardiol Therapeutics Inc., a clinical-stage biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, an ultra-pure and high concentration cannabidiol oral formulation for the treatment of in hospitalized COVID-19 patients with a prior history of risk factors for CVD; and has completed phase I clinical trials for the treatment of acute myocarditis and other inflammatory heart disease. The company is also developing a proprietary subcutaneous formulation of cannabidiol to achieve higher bioavailability for the treatment chronic heart failure. In addition, it develops proprietary nanotechnology to enable the distribution of water insoluble drugs within the blood circulation, enhance pharmacokinetics, and facilitate drug accumulation in the failing heart. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.",0,0,0
CLSN,Celsion Corp,Common Stock,1.06,$90.02M,https://finance.yahoo.com/quote/CLSN/profile?p=CLSN,"Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and vaccines. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product, which is in Phase II clinical trials for the localized treatment of ovarian cancers. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.",1,1,0
MBRX,Moleculin Biotech Inc,Common Stock,3.19,$90.17M,https://finance.yahoo.com/quote/MBRX/profile?p=MBRX,"Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and hematologic malignancies. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of topical treatment of cutaneous T-cell lymphoma. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and antimetabolites, targeting glycolysis and glycosylation. The company has partnerships and collaboration agreement with MD Anderson, DERMIN Sp. z o. o., Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.",0,0,0
APRE,Aprea Therapeutics Inc,Common Stock,4.51,$90.26M,https://finance.yahoo.com/quote/APRE/profile?p=APRE,"Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.",0,0,0
AEZS,AEterna Zentaris Inc,Common Stock,0.7748,$91.73M,https://finance.yahoo.com/quote/AEZS/profile?p=AEZS,"Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maximilians-University Wuerzburg for the development of an oral prophylactic bacterial vaccine against COVID-19 disease; development, manufacture, and commercialization of targeted immunosuppressive therapeutic proteins for the treatment of neuromyelitis optica spectrum disorder. It also has a license agreement with Consilient Health Ltd. and Novo Nordisk Biopharm Limited for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.",0,0,0
ALRN,Aileron Therapeutics Inc,Common Stock,1.03,$93.04M,https://finance.yahoo.com/quote/ALRN/profile?p=ALRN,"Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. Aileron Therapeutics, Inc. has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Watertown, Massachusetts.",0,1,0
CNTMF,Cansortium Inc,Common Stock,0.84,$93.32M,https://finance.yahoo.com/quote/CNTMF/profile?p=CNTMF,"Cansortium Inc., through its subsidiaries, produces and sells medical cannabis in the United States. The company engages in the cultivation, processing, retail, and distribution activities. Its medical cannabis products are offered in oral drops, capsules, suppositories, topicals, syringes, dried flower, prerolls, cartridges, and edibles. The company provides its products under the Fluent brand name. Cansortium Inc. was incorporated in 2018 and is headquartered in Miami, Florida.",0,0,0
AIM,Aim Immunotech Inc,Common Stock,2.0,$94.71M,https://finance.yahoo.com/quote/AIM/profile?p=AIM,"AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, and HIV. The company also provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; and Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1990 and is headquartered in Ocala, Florida.",0,0,0
ACST,Acasti Pharma Inc,Common Stock,0.4657,$95.31M,https://finance.yahoo.com/quote/ACST/profile?p=ACST,"Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.",1,1,0
ARMP,Armata Pharmaceuticals Inc,Common Stock,3.85,$96.89M,https://finance.yahoo.com/quote/ARMP/profile?p=ARMP,"Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for the treatment of Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing proprietary synthetic phage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.",0,0,0
OGEN,Oragenics Inc,Common Stock,0.7924,$97.00M,https://finance.yahoo.com/quote/OGEN/profile?p=OGEN,"Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Its lead product candidate under development is OG716, an antibiotic for the treatment of Clostridium difficile. The company also engages in the development and commercialization of Terra CoV-2, a vaccine product candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. Its product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. The company has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and production of lantibiotics, a peptide antibiotic that are naturally produced in gram-positive bacteria. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.",0,0,0
XPHYF,XPhyto Therapeutics Corp,Common Stock,1.4192,$97.20M,https://finance.yahoo.com/quote/XPHYF/profile?p=XPHYF,"XPhyto Therapeutics Corp., through its subsidiaries, operates as a biopharma, diagnostics, and cannabis science company in Canada and Germany. It is involved in the production, cultivation, extraction, isolation, formulation, delivery, and sale of medicinal cannabis. The company also provides contract development and consulting services. XPhyto Therapeutics Corp. has development, technology purchase and license agreement with 3a-Diagnostics GmbH for the development and commercialization of real-time, low-cost and easy-to-use screening tests using 3a's pathogen specific biosensors and XPhyto's oral dissolvable drug delivery platform. XPhyto Therapeutics Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.",0,0,0
SHWZ,Medicine Man Technologies Inc,Common Stock,2.38,$97.36M,https://finance.yahoo.com/quote/SHWZ/profile?p=SHWZ,"Medicine Man Technologies, Inc., doing business as Schwazze, operates as a cannabis company. The company provides cannabis products for various edible companies; and vape cartridges and syringes. As of March 17, 2021, it owned and operated 17 dispensaries in Colorado under the brand name Star Buds. In addition, the company provides consulting services for cannabis businesses; and Three A Light, cannabis grower's guide book. Further, it manufactures, wholesales, and retails various plant nutrients for cannabis; and supplies hydroponics and indoor gardening supplies. The company was incorporated in 2014 and is based in Denver, Colorado.",0,0,0
ISR,IsoRay Inc,Common Stock,0.7061,$98.26M,https://finance.yahoo.com/quote/ISR/profile?p=ISR,"Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.",0,0,0
ARPO,Aerpio Pharmaceuticals Inc,Common Stock,2.16,$98.28M,https://finance.yahoo.com/quote/ARPO/profile?p=ARPO,"Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.",0,1,0
GANX,Gain Therapeutics Inc,Common Stock,8.3,$98.58M,https://finance.yahoo.com/quote/GANX/profile?p=GANX,"Gain Therapeutics, Inc., a development stage biotechnology company, engages in developing various therapeutics to treat diseases caused by protein misfolding. It focuses rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, treating the underlying disease. It is developing structurally targeted allosteric regulator candidates in various preclinical studies to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.",0,0,0
OTIC,Otonomy Inc,Common Stock,1.75,$99.08M,https://finance.yahoo.com/quote/OTIC/profile?p=OTIC,"Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of MÃ©niÃ¨re's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.",1,1,0
LJPC,La Jolla Pharmaceutical Co,Common Stock,3.74,$99.17M,https://finance.yahoo.com/quote/LJPC/profile?p=LJPC,"La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company was incorporated in 1989 and is headquartered in San Diego, California.",0,0,0
PCSA,Processa Pharmaceuticals Inc,Common Stock,6.36,$100.74M,https://finance.yahoo.com/quote/PCSA/profile?p=PCSA,"Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It has a license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was incorporated in 2011 and is based in Hanover, Maryland.",0,1,0
ETTX,Entasis Therapeutics Holdings Inc,Common Stock,2.38,$100.89M,https://finance.yahoo.com/quote/ETTX/profile?p=ETTX,"Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate containing zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts.",1,1,0
FSTX,F-star Therapeutics Inc,Common Stock,5.3,$102.45M,https://finance.yahoo.com/quote/FSTX/profile?p=FSTX,"F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.",0,1,0
PSTI,Pluristem Therapeutics Inc,Common Stock,3.41,$102.84M,https://finance.yahoo.com/quote/PSTI/profile?p=PSTI,"Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.",1,1,0
NYMX,Nymox Pharmaceutical Corp,Common Stock,1.54,$103.11M,https://finance.yahoo.com/quote/NYMX/profile?p=NYMX,"Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, The Bahamas.",1,1,1
AGRX,Agile Therapeutics Inc,Common Stock,1.21,$103.23M,https://finance.yahoo.com/quote/AGRX/profile?p=AGRX,"Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.",0,0,0
AYTU,Aytu BioPharma Inc,Common Stock,4.14,$103.45M,https://finance.yahoo.com/quote/AYTU/profile?p=AYTU,"Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Englewood, Colorado.",0,0,0
GLYC,GlycoMimetics Inc,Common Stock,2.05,$104.11M,https://finance.yahoo.com/quote/GLYC/profile?p=GLYC,"GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359 to target E-selectin and a chemokine receptors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.",1,0,0
PRPH,ProPhase Labs Inc,Common Stock,7.35,$105.02M,https://finance.yahoo.com/quote/PRPH/profile?p=PRPH,"ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; and offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation PCR tests through saliva and nasal swab methods, as well as other respiratory pathogen panel testing services, including Influenza A and B, and others. It serves consumer products companies, as well as large national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was incorporated in 1989 and is headquartered in Garden City, New York.",0,0,0
CNCE,Concert Pharmaceuticals Inc,Common Stock,3.46,$105.53M,https://finance.yahoo.com/quote/CNCE/profile?p=CNCE,"Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. Its lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert Pharmaceuticals has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.",1,1,0
AXIM,AXIM Biotechnologies Inc,Common Stock,0.755,$105.67M,https://finance.yahoo.com/quote/AXIM/profile?p=AXIM,"AXIM Biotechnologies, Inc., a preclinical stage research and development company focuses on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). The company is developing NeuCovix, a rapid diagnostic test measuring levels of functional neutralizing antibodies to prevent SARS-CoV-2 from entering the host cells; and ImmunoPass, a rapid serological diagnostic test that measures SARS-CoV-2 neutralizing antibodies within 10 minutes. It is also developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis; and SPX-1009, an anti-metastatic treatment to measure levels of quiescin sulfhydryl oxidase I. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is headquartered in San Diego, California.",0,0,0
CAPR,Capricor Therapeutics Inc,Common Stock,4.78,$106.15M,https://finance.yahoo.com/quote/CAPR/profile?p=CAPR,"Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.",0,1,0
ROMJF,Rubicon Organics Inc,Common Stock,1.99,$106.72M,https://finance.yahoo.com/quote/ROMJF/profile?p=ROMJF,"Rubicon Organics Inc. produces and sells organic cannabis in Canada. The company processes organic cannabis at its federally licensed 125,000 square foot facility in Delta, British Columbia and sells under its wholly owned and other licensed brands. Rubicon Organics Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.",0,0,0
GLTO,Galecto Inc,Common Stock,4.46,$107.11M,https://finance.yahoo.com/quote/GLTO/profile?p=GLTO,"Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.",0,1,0
DYAI,Dyadic International Inc,Common Stock,3.4,$107.19M,https://finance.yahoo.com/quote/DYAI/profile?p=DYAI,"Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.",0,0,0
COCP,Cocrystal Pharma Inc,Common Stock,1.1,$107.22M,https://finance.yahoo.com/quote/COCP/profile?p=COCP,"Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.",0,1,0
IFRX,InflaRx NV,Common Stock,2.55,$108.72M,https://finance.yahoo.com/quote/IFRX/profile?p=IFRX,"InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.",0,1,0
CMPI,Checkmate Pharmaceuticals Inc,Common Stock,5.09,$110.29M,https://finance.yahoo.com/quote/CMPI/profile?p=CMPI,"Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naÃ¯ve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.",0,1,0
GNCA,Genocea Biosciences Inc,Common Stock,2.03,$110.50M,https://finance.yahoo.com/quote/GNCA/profile?p=GNCA,"Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell therapy; and GEN-009, a neoantigen vaccine candidate, delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.",0,0,0
NBSE,NeuBase Therapeutics Inc,Common Stock,3.54,$111.24M,https://finance.yahoo.com/quote/NBSE/profile?p=NBSE,"NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.",0,0,0
MDWD,MediWound Ltd,Common Stock,3.99,$111.70M,https://finance.yahoo.com/quote/MDWD/profile?p=MDWD,"MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.",0,1,0
EYEN,Eyenovia Inc,Common Stock,4.37,$111.96M,https://finance.yahoo.com/quote/EYEN/profile?p=EYEN,"Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print (MAP) platform technology. The company focuses on to develop clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. Its pipelines focus on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates in pipeline include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.",1,1,0
LGVN,Longeveron INC,Common Stock,6.14,$112.39M,https://finance.yahoo.com/quote/LGVN/profile?p=LGVN,"Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.",0,0,1
EVGN,Evogene Ltd,Common Stock,2.94,$113.97M,https://finance.yahoo.com/quote/EVGN/profile?p=EVGN,"Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.",0,0,0
MEDXF,Medexus Pharmaceuticals Inc,Common Stock,6.03,$114.87M,https://finance.yahoo.com/quote/MEDXF/profile?p=MEDXF,"Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis psoriasis, and juvenile idiopathic arthritis; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also include Treosulfan, a conditioning agent used prior to stem cell transplantation; and Triamcinolone Hexacetonide for intra-articular, intrasynovial, or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was incorporated in 2013 and is based in Verdun, Canada.",0,0,0
PTN,Palatin Technologies Inc.,Common Stock,0.514,$115.05M,https://finance.yahoo.com/quote/PTN/profile?p=PTN,"Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.",0,0,0
VYGR,Voyager Therapeutics Inc,Common Stock,3.23,$116.20M,https://finance.yahoo.com/quote/VYGR/profile?p=VYGR,"Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.",0,0,1
NXGWF,Next Green Wave Holdings Inc,Common Stock,0.62475,$116.22M,https://finance.yahoo.com/quote/NXGWF/profile?p=NXGWF,"Next Green Wave Holdings Inc. cultivates and distributes medicinal and recreational cannabis in California. It is also involved in the processing, production, and packaging of dry flower, cannabis oils, and concentrates. The company offers its products under the Loki the Dog, Carey Hart, King Louie, Sketchy Tank, Junkyard, SD Cannabis, Thorn St. Brewing, Toy Machine Co, and Junkyard brands. The company was formerly known as Crossgate Capital Corporation and changed its name to Next Green Wave Holdings Inc. in August 2018. Next Green Wave Holdings Inc. was incorporated in 2011 and is based in Vancouver, Canada.",0,0,0
LPCN,Lipocine Inc,Common Stock,1.34,$116.54M,https://finance.yahoo.com/quote/LPCN/profile?p=LPCN,"Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH); TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.",0,1,0
SLHG,Skylight Health Group Inc,Common Stock,3.29,$116.67M,https://finance.yahoo.com/quote/SLHG/profile?p=SLHG,"Skylight Health Group Inc. operates as a healthcare services and technology company in the United States, Canada, the United Kingdom, and Colombia. It operates the US multi-state primary care health network that comprises of physical practices, which provides a range of services from primary care, sub-specialty, allied health, and laboratory/diagnostic testing. The company also owns and operates a proprietary electronic health record system that supports the delivery of care to patients through telemedicine and other remote monitoring system integrations. In addition, it offers a disruptive subscription-based telemedicine service for the un/under-insured population. The company was formerly known as CB2 Insights Inc. and changed its name to Skylight Health Group Inc. in November 2020. Skylight Health Group Inc. was founded in 2014 and is headquartered in Mississauga, Canada.",0,0,0
ORGS,Orgenesis Inc,Common Stock,4.99,$117.01M,https://finance.yahoo.com/quote/ORGS/profile?p=ORGS,"Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. sThe company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. The company was incorporated in 2008 and is based in Germantown, Maryland.",0,0,0
VBLT,Vascular Biogenics Ltd,Common Stock,2.02,$117.34M,https://finance.yahoo.com/quote/VBLT/profile?p=VBLT,"Vascular Biogenics Ltd., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; and VB-703 for NASH and renal fibrosis. In addition, the company is developing VB-201, a Lecinoxoid-based product candidate to treat atherosclerosis that has completed Phase II clinical; and is in Phase II exploratory trials for COVID-19, as well as in pre-clinical stage for the treatment of NASH and renal fibrosis. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.",1,1,0
LOVFF,Cannara Biotech Inc,Common Stock,0.1404,$117.89M,https://finance.yahoo.com/quote/LOVFF/profile?p=LOVFF,"Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-infused products in Canada. It also offers hemp based CBD products through e-commerce platform. The company was incorporated in 2017 and is headquartered in Montreal, Canada.",0,0,0
HEPA,Hepion Pharmaceuticals Inc,Common Stock,1.56,$118.15M,https://finance.yahoo.com/quote/HEPA/profile?p=HEPA,"Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.",0,1,0
ELOX,Eloxx Pharmaceuticals Inc,Common Stock,1.39,$118.88M,https://finance.yahoo.com/quote/ELOX/profile?p=ELOX,"Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Waltham, Massachusetts.",0,1,0
XCUR,Exicure Inc,Common Stock,1.39,$119.67M,https://finance.yahoo.com/quote/XCUR/profile?p=XCUR,"Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNAÂbased therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; and license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome. The company was founded in 2011 and is headquartered in Chicago, Illinois.",0,0,0
BCLI,Brainstorm Cell Therapeutics,Common Stock,3.57,$120.94M,https://finance.yahoo.com/quote/BCLI/profile?p=BCLI,"Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.",1,1,1
IMV,IMV Inc,Common Stock,1.74,$122.03M,https://finance.yahoo.com/quote/IMV/profile?p=IMV,"IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a second-generation vaccine against severe acute respiratory syndrome coronavirus 2; and DPX-RSV, a vaccine candidate, which has completed Phase I clinical trials for the treatment of respiratory syncytial virus strain A, as well as DPX-SurMAGE for the treatment of bladder cancer and DPX-BRAF to treat melanoma patients. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.",0,1,0
ENTX,Entera Bio Ltd,Common Stock,5.21,$122.21M,https://finance.yahoo.com/quote/ENTX/profile?p=ENTX,"Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.",0,1,0
GDNSF,Goodness Growth Holdings Inc,Common Stock,1.585,$122.85M,https://finance.yahoo.com/quote/GDNSF/profile?p=GDNSF,"Goodness Growth Holdings, Inc. operates as a physician-led cannabis company in the United States. It cultivates cannabis; manufactures pharmaceutical-grade cannabis extracts; and sells its products through its network of Green Goods and other retail locations, and third-party dispensaries. The company grows and/or processes cannabis in eight markets and operates 16 dispensaries. The company was formerly known as Vireo Health International Inc. and changed its name to Goodness Growth Holdings, Inc. in June 2021. Goodness Growth Holdings, Inc. is headquartered in Minneapolis, Minnesota.",0,0,0
ONCY,Oncolytics Biotech Inc,Common Stock,2.4,$123.48M,https://finance.yahoo.com/quote/ONCY/profile?p=ONCY,"Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.",0,0,0
AQST,Aquestive Therapeutics Inc,Common Stock,3.51,$123.68M,https://finance.yahoo.com/quote/AQST/profile?p=AQST,"Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.",0,0,0
LQDA,Liquidia Corp,Common Stock,2.45,$123.70M,https://finance.yahoo.com/quote/LQDA/profile?p=LQDA,"Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.",0,0,0
ABEO,Abeona Therapeutics Inc,Common Stock,1.28,$123.77M,https://finance.yahoo.com/quote/ABEO/profile?p=ABEO,"Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.",0,0,0
EVFM,Evofem Biosciences Inc,Common Stock,0.8802,$125.82M,https://finance.yahoo.com/quote/EVFM/profile?p=EVFM,"Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. It has a collaboration agreement with National Community Oncology Dispensing Association, Inc. to educate oncology community about Phexxi. Evofem Biosciences, Inc. is headquartered in San Diego, California.",0,0,0
AXLA,Axcella Health Inc,Common Stock,3.63,$125.99M,https://finance.yahoo.com/quote/AXLA/profile?p=AXLA,"Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. It treats complex diseases and enhances health using endogenous metabolic modulator compositions. The company's lead product candidates include AXA1665 for the treatment of overt hepatic encephalopathy; and AXA1125 for treating non-alcoholic steatohepatitis. It also develops AXA4010, a hematology product candidate; and AXA2678, a muscle product candidate. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.",0,0,0
TGODF,The Green Organic Dutchman Holdings Ltd,Common Stock,0.254,$129.29M,https://finance.yahoo.com/quote/TGODF/profile?p=TGODF,"The Green Organic Dutchman Holdings Ltd., through its subsidiaries, produces and sells organic cannabis in Canada. It offers organic cannabis products, such as cannabis plants, cannabis plant seeds, dried cannabis, fresh cannabis, cannabis oils, cannabis topicals, cannabis extracts, and edible cannabis to retailers or distributors, and federal licensed entities. The Green Organic Dutchman Holdings Ltd. was incorporated in 2016 and is headquartered in Mississauga, Canada.",0,0,0
CBIO,Catalyst Biosciences Inc,Common Stock,4.32,$129.79M,https://finance.yahoo.com/quote/CBIO/profile?p=CBIO,"Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company engineer proteases to develop improved or novel molecules to treat diseases that result from dysregulation of the complement and coagulation cascades. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously administered engineered coagulation; and Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. The company's pipeline also includes a preclinical program partnered with Biogen International GmbH for dry age-related macular degeneration (AMD); factor I protease for SQ prophylaxis in patients with complement factor I deficiency and C4b-degraders designed to target disorders of the classical complement pathway, as well as other complement programs. The company also develops CB 4332 intended for lifelong prophylactic SQ administration in individuals with CFI deficiency; and CB 2782-PEG, a C3 degrader product candidate in preclinical development for the treatment of dry AMD. It has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.",0,0,0
IPIX,Innovation Pharmaceuticals Inc,Common Stock,0.315,$130.14M,https://finance.yahoo.com/quote/IPIX/profile?p=IPIX,"Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It develops Brilacidin, a lead drug compound for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company also develops Kevetrin, a lead anti-cancer compound for treating ovarian cancer. It has license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.",0,0,0
RVVTF,Revive Therapeutics Ltd,Common Stock,0.4121,$130.64M,https://finance.yahoo.com/quote/RVVTF/profile?p=RVVTF,"Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers novel cannabinoid-centric treatments for liver diseases, inflammatory diseases, and skin disorders. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and coronavirus disease; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocybin oral formulations for the treatment of depression, anxiety, etc.; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has a research collaboration agreement with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; research agreement with the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; and collaboration with University of Health Sciences Antigua to pioneer clinical research of psychedelics. The company was incorporated in 2012 and is headquartered in Toronto, Canada.",1,0,0
ODT,Odonate Therapeutics Inc,Common Stock,3.43,$130.92M,https://finance.yahoo.com/quote/ODT/profile?p=ODT,"Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.",1,1,0
CYCN,Cyclerion Therapeutics Inc,Common Stock,3.36,$130.96M,https://finance.yahoo.com/quote/CYCN/profile?p=CYCN,"Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.",0,1,1
ETON,Eton Pharmaceuticals Inc,Common Stock,5.53,$132.10M,https://finance.yahoo.com/quote/ETON/profile?p=ETON,"Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.",0,0,0
ITRM,Iterum Therapeutics plc,Common Stock,0.7438,$132.74M,https://finance.yahoo.com/quote/ITRM/profile?p=ITRM,"Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.",1,1,0
MDNA,Medicenna Therapeutics Corp,Common Stock,2.53,$133.22M,https://finance.yahoo.com/quote/MDNA/profile?p=MDNA,"Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.",0,1,0
PYPD,PolyPid Ltd,Common Stock,7.24,$133.84M,https://finance.yahoo.com/quote/PYPD/profile?p=PYPD,"PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.",1,0,0
ANIX,Anixa Biosciences Inc,Common Stock,4.81,$134.48M,https://finance.yahoo.com/quote/ANIX/profile?p=ANIX,"Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.",0,0,0
INFI,Infinity Pharmaceuticals Inc,Common Stock,2.45,$134.74M,https://finance.yahoo.com/quote/INFI/profile?p=INFI,"Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts.",0,0,0
SLS,SELLAS Life Sciences Group Inc,Common Stock,8.81,$134.93M,https://finance.yahoo.com/quote/SLS/profile?p=SLS,"SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It also develops nelipepimut-S, a cancer immunotherapy that is in Phase 2b clinical trials for the treatment of early stage breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.",1,1,0
LOGC,LogicBio Therapeutics Inc,Common Stock,4.23,$135.07M,https://finance.yahoo.com/quote/LOGC/profile?p=LOGC,"LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as two additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company also has a strategic collaboration and option agreement with CANbridge Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.",0,0,0
PHGE,BiomX Inc,Common Stock,4.67,$135.62M,https://finance.yahoo.com/quote/PHGE/profile?p=PHGE,"BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). The company's lead product candidate BX001, which is in Phase II that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type. Its products under development include BX003 to treat acne-prone skin, IBD, and PSC; BX004, a therapeutic phage product candidate for chronic respiratory infections caused by pseudomonas aeruginosa; and BX005, a topical phage product candidate for staphylococcus aureus, a bacterium associated with the development and exacerbation of inflammation in atopic dermatitis, as well as CRC program targets strains of bacteria found in CRC tumors. The company has license agreement with Keio University and JSR Corporation to bacterial targets that are related to IBD and the phage to eradicate these bacterial targets. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.",0,1,0
CLXT,Calyxt Inc,Common Stock,3.78,$135.78M,https://finance.yahoo.com/quote/CLXT/profile?p=CLXT,"Calyxt, Inc., a technology company, focuses on delivering plant-based solutions in the United States. It engages in the development of improved digestibility alfalfa; high fiber wheat; high oleic low linolenic soybeans; winter oats; hemp; fat soybeans; and cold storable potatoes. As of March 4, 2021, the company had nine projects at Phase I stage or later in development across alfalfa, hemp, oats, soybeans, and wheat. Calyxt, Inc. has a research collaboration with NRGene, which includes the adoption of NRGene's cloud-based genomics platform to support various research projects; and a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and various geographies outside the United States. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.",0,0,0
ENLV,Enlivex Therapeutics Ltd,Common Stock,7.7,$136.01M,https://finance.yahoo.com/quote/ENLV/profile?p=ENLV,"Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel.",0,0,0
TLLTF,TILT Holdings Inc,Common Stock,0.451,$136.09M,https://finance.yahoo.com/quote/TLLTF/profile?p=TLLTF,"TILT Holdings Inc provides various products and services across the cannabis industry in the United States, Canada, Israel, Mexico, South America, and the European Union. It operates through Cannabis, Technology/Distribution, Accessories, and Other segments. The company engages in the cultivation, production, and retail of cannabis products; manufacture and distribution of electronic and non-nicotine devices and systems; and focuses on greenhouse cultivation and CO2 extraction. It also offers a range of products and services across the cannabis industry; and logistic operations and software solutions throughout the cannabis supply chain. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts.",0,0,0
ATNM,Actinium Pharmaceuticals Inc,Common Stock,6.97,$136.52M,https://finance.yahoo.com/quote/ATNM/profile?p=ATNM,"Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19 CAR T-cell therapy with memorial sloan kettering cancer center. The company is also developing a multi-disease, multi-target pipeline of clinical-stage antibody radiation-conjugates targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a range of hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas Pharma, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York.",1,1,0
XFOR,X4 Pharmaceuticals Inc,Common Stock,5.79,$136.96M,https://finance.yahoo.com/quote/XFOR/profile?p=XFOR,"X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rear diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and WaldenstrÃ¶m macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.",1,1,0
GNPX,Genprex Inc,Common Stock,3.01,$137.36M,https://finance.yahoo.com/quote/GNPX/profile?p=GNPX,"Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.",0,0,0
OPTN,Optinose Inc,Common Stock,2.71,$138.09M,https://finance.yahoo.com/quote/OPTN/profile?p=OPTN,"OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase 3b clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.",1,0,0
ASMB,Assembly Biosciences Inc,Common Stock,3.54,$138.14M,https://finance.yahoo.com/quote/ASMB/profile?p=ASMB,"Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, Ltd.; and Arbutus Biopharma Corporation, as well as strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.",0,1,0
YCBD,cbdMD Inc,Common Stock,2.59,$138.22M,https://finance.yahoo.com/quote/YCBD/profile?p=YCBD,"cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. It owns and operates consumer hemp-based CBD brands, such as cbdMD and Paw CBD. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. The company also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. It distributes its products through its e-commerce Website, third party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was founded in 2015 and is headquartered in Charlotte, North Carolina.",0,0,0
VYNE,VYNE Therapeutics Inc,Common Stock,2.72,$139.26M,https://finance.yahoo.com/quote/VYNE/profile?p=VYNE,"VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.",0,1,0
LTRN,Lantern Pharma Inc,Common Stock,12.91,$140.66M,https://finance.yahoo.com/quote/LTRN/profile?p=LTRN,"Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.",0,1,0
VRDN,Viridian Therapeutics Inc,Common Stock,16.8,$140.78M,https://finance.yahoo.com/quote/VRDN/profile?p=VRDN,"Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.",0,0,0
MTNB,Matinas BioPharma Holdings Inc,Common Stock,0.7265,$140.96M,https://finance.yahoo.com/quote/MTNB/profile?p=MTNB,"Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.",0,1,0
ACRX,AcelRx Pharmaceuticals Inc,Common Stock,1.2,$141.73M,https://finance.yahoo.com/quote/ACRX/profile?p=ACRX,"AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.",0,0,0
SCYX,SCYNEXIS Inc,Common Stock,7.32,$142.35M,https://finance.yahoo.com/quote/SCYX/profile?p=SCYX,"SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.",0,1,0
ATBPF,Antibe Therapeutics Inc,Common Stock,2.72,$142.45M,https://finance.yahoo.com/quote/ATBPF/profile?p=ATBPF,"Antibe Therapeutics Inc., a biotechnology company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.",0,1,0
CALA,Calithera Biosciences Inc,Common Stock,1.99,$142.91M,https://finance.yahoo.com/quote/CALA/profile?p=CALA,"Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor that is in Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and CB-708, an orally administered small molecule inhibitor of CD73, as well as CB-668, an inhibitor of the enzyme IL4I1. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.",0,1,0
IMRA,Imara Inc,Common Stock,5.77,$143.95M,https://finance.yahoo.com/quote/IMRA/profile?p=IMRA,"IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and Ã-thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.",0,1,0
QLI,Qilian International Holding Group Ltd,Common Stock,4.34,$144.07M,https://finance.yahoo.com/quote/QLI/profile?p=QLI,"Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs) and traditional Chinese medicine derivative (TCMD) products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings comprising Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.",0,0,0
AYLA,Ayala Pharmaceuticals Inc,Common Stock,11.7,$144.99M,https://finance.yahoo.com/quote/AYLA/profile?p=AYLA,"Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.",0,1,0
SVRA,Savara Inc,Common Stock,1.31,$146.60M,https://finance.yahoo.com/quote/SVRA/profile?p=SVRA,"Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.",1,1,0
MMNFF,MedMen Enterprises Inc,Common Stock,0.2425,$147.15M,https://finance.yahoo.com/quote/MMNFF/profile?p=MMNFF,"MedMen Enterprises Inc., through its subsidiaries, operates as a cannabis company in the United States. The company cultivates, produces, distributes, and retails recreational and medicinal cannabis under the [statemade], LuxLyte, and MedMen Red brand names. It operates 25 retail stores in 6 states. MedMen Enterprises Inc. was founded in 2010 and is headquartered in Culver City, California.",0,0,0
CATB,Catabasis Pharmaceuticals Inc,Common Stock,1.71,$147.83M,https://finance.yahoo.com/quote/CATB/profile?p=CATB,"Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.",0,0,0
LBPH,Longboard Pharmaceuticals Inc,Common Stock,9.21,$149.25M,https://finance.yahoo.com/quote/LBPH/profile?p=LBPH,"Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.",0,0,0
SIOX,Sio Gene Therapies Inc,Common Stock,2.11,$150.25M,https://finance.yahoo.com/quote/SIOX/profile?p=SIOX,"Sio Gene Therapies, Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease; AXO-AAV-GM1, an investigational gene therapy , which is in Phase I/II clinical trials for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2, an investigational gene therapy, which is in Phase I/II clinical trials for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.",0,1,0
SCPH,scPharmaceuticals Inc,Common Stock,5.72,$150.45M,https://finance.yahoo.com/quote/SCPH/profile?p=SCPH,"scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of proprietary buffered formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.",0,0,0
NOVN,Novan Inc,Common Stock,8.04,$151.02M,https://finance.yahoo.com/quote/NOVN/profile?p=NOVN,"Novan, Inc., a clinical development-stage biotechnology company, provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Morrisville, North Carolina.",0,0,0
ENSC,Ensysce Biosciences Inc,Common Stock,6.25,$152.14M,https://finance.yahoo.com/quote/ENSC/profile?p=ENSC,"Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is based in La Jolla, California.",0,0,0
GALT,Galectin Therapeutics Inc,Common Stock,2.7,$154.53M,https://finance.yahoo.com/quote/GALT/profile?p=GALT,"Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.",1,1,0
ADMP,Adamis Pharmaceuticals Corp,Common Stock,1.03,$154.84M,https://finance.yahoo.com/quote/ADMP/profile?p=ADMP,"Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candidates for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.",0,0,0
TTOO,T2 Biosystems Inc,Common Stock,1.06,$156.11M,https://finance.yahoo.com/quote/TTOO/profile?p=TTOO,"T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida Panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it provides T2Bacteria Panel, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2SARS-CoV-2 Panel, a COVID-19 molecular diagnostic test; and T2Resistance Panel for the early and sensitive detection of carbapenemase-resistance markers. Further, it develops T2Cauris Panel, a multi-drug resistant pathogen; and T2Lyme Panel for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.",0,0,0
CFRX,ContraFect Corp,Common Stock,4.18,$156.15M,https://finance.yahoo.com/quote/CFRX/profile?p=CFRX,"ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staph aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which in preclinical trials for the treatment of pseudomonas aeruginosa infections, including ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. The company has a collaboration research agreement with The Rockefeller University to identification of novel lysin therapeutic candidates targeting gram-negative pathogens. It also initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients. The company was incorporated in 2008 and is headquartered in Yonkers, New York.",1,1,0
LRMR,Larimar Therapeutics Inc,Common Stock,10.64,$158.60M,https://finance.yahoo.com/quote/LRMR/profile?p=LRMR,"Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania.",0,0,0
ARDX,Ardelyx Inc,Common Stock,1.73,$158.92M,https://finance.yahoo.com/quote/ARDX/profile?p=ARDX,"Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.",1,1,0
AGTC,Applied Genetic Technologies Corp,Common Stock,3.77,$159.90M,https://finance.yahoo.com/quote/AGTC/profile?p=AGTC,"Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.",0,0,0
MIST,Milestone Pharmaceuticals USA Inc,Common Stock,5.48,$162.66M,https://finance.yahoo.com/quote/MIST/profile?p=MIST,"Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as in the Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate, and other cardiovascular indications. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil in patients with paroxysmal supraventricular tachycardia and additional cardiovascular conditions in Greater China. The company was incorporated in 2003 and is headquartered in MontrÃ©al, Canada.",1,1,0
HTBX,Heat Biologics Inc,Common Stock,6.6,$163.31M,https://finance.yahoo.com/quote/HTBX/profile?p=HTBX,"Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer; and HS-130 that is in phase I clinical trial for the treatment of advanced solid tumors. Its preclinical stage products include PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25; TNFRSF25 modulators for various immunotherapy approaches; and COVID-19 vaccine. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.",0,1,0
ANEB,Anebulo Pharmaceuticals Inc,Common Stock,7.1248,$163.42M,https://finance.yahoo.com/quote/ANEB/profile?p=ANEB,"Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.",0,0,0
CASI,CASI Pharmaceuticals Inc,Common Stock,1.18,$163.56M,https://finance.yahoo.com/quote/CASI/profile?p=CASI,"CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. The company offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma, which has completed Phase I studies in China. It also provides CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase 1/2a trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome, as well as solid tumors and lymphomas. In addition, the company offers CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors; ZEVALIN to treat patients with NHL; and MARQIBO for the treatment of adult patients with Philadelphia chromosome-negative ALL. It has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. The company also has distribution agreements with China Resources Guokang Pharmaceuticals Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.",0,0,0
VTVT,vTv Therapeutics Inc,Common Stock,2.02,$164.08M,https://finance.yahoo.com/quote/VTVT/profile?p=VTVT,"vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates to fill unmet medical needs. The company is developing TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant PDE4 inhibitor that addresses inflammatory diseases. It is also involved in the clinical development of other programs, including a small molecule GLP-1r agonist; the PDE4 inhibitor; HPP737, a PPAR-delta agonist; and an Nrf2 activator through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.",0,0,0
OBSV,ObsEva SA,Common Stock,2.63,$165.18M,https://finance.yahoo.com/quote/OBSV/profile?p=OBSV,"ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.",0,0,0
CBWTF,Auxly Cannabis Group Inc,Common Stock,0.2028,$167.31M,https://finance.yahoo.com/quote/CBWTF/profile?p=CBWTF,"Auxly Cannabis Group Inc., a cannabis company, provides cannabis products to the medical, wellness, and adult-use markets in Canada. The company engages in the cultivation, development, and distribution of cannabis products. It offers products such as, soft chews, vape cartridges, vape pens, pre-rolled cannabis, chocolates, cannabis oil spray, and oil drops through retail stores under the Kolab Project, Foray, and Dosecan brand names. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. Auxly Cannabis Group Inc. was incorporated in 1987 and is based in Vancouver, Canada.",0,0,0
SGTX,Sigilon Therapeutics Inc,Common Stock,5.67,$167.74M,https://finance.yahoo.com/quote/SGTX/profile?p=SGTX,"Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.",0,0,0
STSA,Satsuma Pharmaceuticals Inc,Common Stock,5.31,$168.05M,https://finance.yahoo.com/quote/STSA/profile?p=STSA,"Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.",1,1,0
SYBX,Synlogic Inc,Common Stock,3.26,$168.10M,https://finance.yahoo.com/quote/SYBX/profile?p=SYBX,"Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase II clinical trial to treat phenylketonuria (PKU), as well as pre-clinical stage product SYNB1934 for the treatment of PKU; and SYNB8802 that is in Phase I clinical trial for the treatment of Enteric Hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.",0,1,0
SBBP,Strongbridge Biopharma PLC,Common Stock,2.57,$168.30M,https://finance.yahoo.com/quote/SBBP/profile?p=SBBP,"Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that has completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.",1,1,0
PHAS,PhaseBio Pharmaceuticals Inc,Common Stock,3.56,$168.31M,https://finance.yahoo.com/quote/PHAS/profile?p=PHAS,"PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.",1,1,0
EQ,Equillium Inc,Common Stock,5.49,$169.59M,https://finance.yahoo.com/quote/EQ/profile?p=EQ,"Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.",0,0,0
APTX,Aptinyx Inc,Common Stock,2.57,$171.12M,https://finance.yahoo.com/quote/APTX/profile?p=APTX,"Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.",0,1,0
FENC,Fennec Pharmaceuticals Inc,Common Stock,6.61,$172.14M,https://finance.yahoo.com/quote/FENC/profile?p=FENC,"Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.",1,1,0
CRBP,Corbus Pharmaceuticals Holdings Inc,Common Stock,1.47,$173.80M,https://finance.yahoo.com/quote/CRBP/profile?p=CRBP,"Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.",1,1,0
MRKR,Marker Therapeutics Inc,Common Stock,2.19,$174.33M,https://finance.yahoo.com/quote/MRKR/profile?p=MRKR,"Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.",0,1,0
DBTX,Decibel Therapeutics Inc,Common Stock,7.21,$174.81M,https://finance.yahoo.com/quote/DBTX/profile?p=DBTX,"Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.",0,0,0
AVEO,AVEO Pharmaceuticals Inc,Common Stock,5.27,$175.93M,https://finance.yahoo.com/quote/AVEO/profile?p=AVEO,"AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; AstraZeneca PLC; and Bristol Myers Squibb. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.",0,1,0
CLGN,CollPlant Biotechnologies Ltd,Common Stock,16.9,$178.28M,https://finance.yahoo.com/quote/CLGN/profile?p=CLGN,"CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants that are used for the regeneration of breast tissue; injectable implants to promote breast tissue regeneration; VergenixSTR, a soft tissue repair matrix intended for treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.",0,0,0
MNOV,Medicinova Inc,Common Stock,3.79,$178.98M,https://finance.yahoo.com/quote/MNOV/profile?p=MNOV,"MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.",0,0,0
IMNM,Immunome Inc,Common Stock,16.08,$179.29M,https://finance.yahoo.com/quote/IMNM/profile?p=IMNM,"Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.",0,0,0
MYMD,MyMD Pharmaceuticals Inc,Common Stock,4.94,$182.92M,https://finance.yahoo.com/quote/MYMD/profile?p=MYMD,"MyMD Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the development of drug products in the targeting of aging and age-related diseases; autoimmune diseases; and chronic pain, anxiety, and sleep disorders. It commercializes MYMD-1, a novel therapeutic to impact conditions related to immunometabolic dysregulation; and SUPERA-1R, a synthetic cannabidiol that offers bioavailability and potency than botanicals. The company was incorporated in 2014 and is based in Tampa, Florida.",0,0,0
ONCT,Oncternal Therapeutics Inc,Common Stock,4.04,$186.12M,https://finance.yahoo.com/quote/ONCT/profile?p=ONCT,"Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.; Selexis S.A.; and University of Tennessee Research Foundation. The company is headquartered in San Diego, California.",0,0,0
ZYNE,Zynerba Pharmaceuticals Inc,Common Stock,4.69,$186.87M,https://finance.yahoo.com/quote/ZYNE/profile?p=ZYNE,"Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.",0,0,0
TERN,Terns Pharmaceuticals Inc,Common Stock,8.17,$189.35M,https://finance.yahoo.com/quote/TERN/profile?p=TERN,"Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase I clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Foster City, California.",0,1,0
CABA,Cabaletta Bio Inc,Common Stock,7.8,$190.70M,https://finance.yahoo.com/quote/CABA/profile?p=CABA,"Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.",0,0,0
LCI,Lannett Co Inc.,Common Stock,4.72,$191.07M,https://finance.yahoo.com/quote/LCI/profile?p=LCI,"Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was founded in 1942 and is headquartered in Philadelphia, Pennsylvania.",0,0,0
GMTX,Gemini Therapeutics Inc,Common Stock,4.44,$191.16M,https://finance.yahoo.com/quote/GMTX/profile?p=GMTX,"Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.",0,1,0
PRTG,Portage Biotech Inc,Common Stock,16.36,$196.83M,https://finance.yahoo.com/quote/PRTG/profile?p=PRTG,"Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.",0,0,0
JAGX,Jaguar Health Inc,Common Stock,1.52,$201.86M,https://finance.yahoo.com/quote/JAGX/profile?p=JAGX,"Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.",0,0,0
TCDA,Tricida Inc,Common Stock,4.09,$202.10M,https://finance.yahoo.com/quote/TCDA/profile?p=TCDA,"Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer that has completed phase 3 trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.",1,0,0
CRDF,Cardiff Oncology Inc,Common Stock,5.66,$203.91M,https://finance.yahoo.com/quote/CRDF/profile?p=CRDF,"Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.",0,1,0
UBX,Unity Biotechnology Inc,Common Stock,3.89,$209.55M,https://finance.yahoo.com/quote/UBX/profile?p=UBX,"Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.",0,0,0
CKPT,Checkpoint Therapeutics Inc,Common Stock,2.75,$209.84M,https://finance.yahoo.com/quote/CKPT/profile?p=CKPT,"Checkpoint Therapeutics, Inc., a clinical-stage immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing CK-101, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.",0,0,0
BLU,BELLUS Health Inc,Common Stock,2.72,$211.51M,https://finance.yahoo.com/quote/BLU/profile?p=BLU,"BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. The company was founded in 1993 and is headquartered in Laval, Canada.",0,1,0
ADMA,ADMA Biologics Inc,Common Stock,1.61,$211.51M,https://finance.yahoo.com/quote/ADMA/profile?p=ADMA,"ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.",0,0,0
PIRS,Pieris Pharmaceuticals Inc,Common Stock,3.47,$212.07M,https://finance.yahoo.com/quote/PIRS/profile?p=PIRS,"Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin protein-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-expressing solid tumors. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein targeting 4-1BB and PD-L1 for immuno-oncology diseases; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.",0,1,0
RPHM,Reneo Pharmaceuticals Inc,Common Stock,8.67,$214.20M,https://finance.yahoo.com/quote/RPHM/profile?p=RPHM,"Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.",0,1,0
TFFP,TFF Pharmaceuticals Inc,Common Stock,8.65,$214.33M,https://finance.yahoo.com/quote/TFFP/profile?p=TFFP,"TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform in the United States and Australia. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which has completed Phase I clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in the Phase I clinical trials used for the prevention of lung transplant rejection. It is also developing other dry powder products, such as Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various types of pain; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.",0,0,0
XERS,Xeris Pharmaceuticals inc,Common Stock,3.34,$214.35M,https://finance.yahoo.com/quote/XERS/profile?p=XERS,"Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.",0,1,0
ALPN,Alpine Immune Sciences Inc,Common Stock,9.29,$216.43M,https://finance.yahoo.com/quote/ALPN/profile?p=ALPN,"Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the research, development, and commercialization of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.",0,0,0
ATNF,180 Life Sciences Corp,Common Stock,6.95,$217.84M,https://finance.yahoo.com/quote/ATNF/profile?p=ATNF,"180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California.",0,1,0
ADMS,Adamas Pharmaceuticals Inc,Common Stock,4.97,$217.96M,https://finance.yahoo.com/quote/ADMS/profile?p=ADMS,"Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.",0,0,1
OSMT,Osmotica Pharmaceuticals Plc,Common Stock,3.35,$218.26M,https://finance.yahoo.com/quote/OSMT/profile?p=OSMT,"Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.",1,1,0
SNSE,Sensei Biotherapeutics Inc,Common Stock,7.53,$219.93M,https://finance.yahoo.com/quote/SNSE/profile?p=SNSE,"Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland.",0,0,0
SPRB,Spruce Biosciences Inc,Common Stock,9.72,$221.87M,https://finance.yahoo.com/quote/SPRB/profile?p=SPRB,"Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH with poor disease control; and CAHmelia-204, which is in second Phase 2b clinical trial in adult patients with classic CAH with good disease control. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.",0,1,0
SRRA,Sierra Oncology Inc,Common Stock,17.51,$222.42M,https://finance.yahoo.com/quote/SRRA/profile?p=SRRA,"Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is based in San Mateo, California.",1,0,0
CTIC,CTI BioPharma Corp,Common Stock,2.39,$223.88M,https://finance.yahoo.com/quote/CTIC/profile?p=CTIC,"CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.",1,1,0
GRTX,Galera Therapeutics Inc,Common Stock,9.12,$225.77M,https://finance.yahoo.com/quote/GRTX/profile?p=GRTX,"Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; in phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy; and has completed pilot placebo-controlled Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced pancreatic cancer, as well as in Phase II clinical trial for hospitalized patients with COVID-19 disease. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with SBRT in patients with non-small cell lung cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.",1,1,0
ADVM,Adverum Biotechnologies Inc,Common Stock,2.37,$227.21M,https://finance.yahoo.com/quote/ADVM/profile?p=ADVM,"Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.",0,0,0
KALA,Kala Pharmaceuticals Inc,Common Stock,3.7,$228.83M,https://finance.yahoo.com/quote/KALA/profile?p=KALA,"Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's product candidates include EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development programs comprise KPI-285/KPI-286, a receptor tyrosine kinase inhibitor program for the treatment of various retinal diseases; SEGRM program, a novel class of compounds designed to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway; and surface targeted steroid program (KPI-333), a new chemical entity as a topical steroid that targets the ocular surface. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.",0,0,0
CLVR,Clever Leaves Holdings Inc,Common Stock,9.98,$229.59M,https://finance.yahoo.com/quote/CLVR/profile?p=CLVR,"Clever Leaves Holdings Inc. cultivates, extracts, manufactures, and commercializes pharmaceutical-grade cannabinoid products in Colombia, Portugal, Germany, the United States, and Canada. The company operates through two segments, Cannabinoid and Non-Cannabinoid. It also engages in the formulating, manufacturing, marketing, distributing, and selling of homeopathic and other natural remedies, wellness products, detoxification products, nutraceuticals, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors. Clever Leaves Holdings Inc. is based in New York, New York.",0,0,0
BCEL,Atreca Inc,Common Stock,8.21,$230.26M,https://finance.yahoo.com/quote/BCEL/profile?p=BCEL,"Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology. Atreca, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.",0,0,0
IMUX,Immunic Inc,Common Stock,9.15,$230.99M,https://finance.yahoo.com/quote/IMUX/profile?p=IMUX,"Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.",0,1,0
TRVN,Trevena Inc,Common Stock,1.45,$231.96M,https://finance.yahoo.com/quote/TRVN/profile?p=TRVN,"Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.",0,0,0
CRMD,CorMedix Inc,Common Stock,6.25,$232.13M,https://finance.yahoo.com/quote/CRMD/profile?p=CRMD,"CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.",0,0,0
TYME,Tyme Technologies Inc,Common Stock,1.23,$232.48M,https://finance.yahoo.com/quote/TYME/profile?p=TYME,"Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-19, an oral synthetically produced member of the bile acid family, which is in preclinical stage for the treatment of COVID-19 and disease variants; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; NYU School of Medicine to examine multiple aspects of SM-88 mechanisms; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.",0,1,0
HROW,Harrow Health Inc,Common Stock,9.22,$232.59M,https://finance.yahoo.com/quote/HROW/profile?p=HROW,"Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.",0,0,0
CMPX,Compass Therapeutics Inc,Common Stock,4.6,$233.47M,https://finance.yahoo.com/quote/CMPX/profile?p=CMPX,"Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing antibody therapeutics to treat solid tumors and hematologic malignancies. The company is leveraging its proprietary StitchMabs and common light-chain enabled multi specific platforms to identify multi specifics and combinations of antibody therapeutics that could be advanced to the clinic. Its lead product candidate is CTX-471, a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells that is being evaluated in a Phase 1 study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors and who subsequently relapsed or progressed after a period of stable disease. The company is also developing CTX-8371, a bispecific antibody that targets PD-1 and PD-L1. In addition, it is developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. The company was founded in 2014 and is headquartered in Boston, Massachusetts.",0,0,0
KLDO,Kaleido BioSciences Inc,Common Stock,5.95,$233.85M,https://finance.yahoo.com/quote/KLDO/profile?p=KLDO,"Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.",0,0,0
HOOK,HOOKIPA Pharma Inc,Common Stock,8.26,$234.04M,https://finance.yahoo.com/quote/HOOK/profile?p=HOOK,"HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.",0,1,0
SEEL,Seelos Therapeutics Inc,Common Stock,2.38,$234.20M,https://finance.yahoo.com/quote/SEEL/profile?p=SEEL,"Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.",0,0,0
NEXI,Neximmune Inc,Common Stock,10.74,$234.37M,https://finance.yahoo.com/quote/NEXI/profile?p=NEXI,"NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; and NEXI-002, an autologous cell therapy, which is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.",0,0,0
ACRHF,Acreage Holdings Inc,Common Stock,3.34,$235.18M,https://finance.yahoo.com/quote/ACRHF/profile?p=ACRHF,"Acreage Holdings, Inc., formerly High Street Capital Partners, is a principal investment firm specializing in cannabis industry. Acreage Holdings, Inc. was founded in 2014 and is based in New York, New York.",0,0,0
APTO,Aptose Biosciences Inc,Common Stock,2.7,$235.70M,https://finance.yahoo.com/quote/APTO/profile?p=APTO,"Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the treatment of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed/refractory acute myeloid leukemia. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.",0,0,0
GTBP,GT Biopharma Inc,Common Stock,11.84,$235.79M,https://finance.yahoo.com/quote/GTBP/profile?p=GTBP,"GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops various immuno-oncology product candidates, including GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and other CD33+ hematopoietic malignancies; GTB-C3550, a follow-on to its lead candidates TriKE, GTB-3550; GTB-4550, a single-chain tri-specific single chain variable fragments (scFv) recombinant fusion protein conjugate for the treatment of PD-L1+ solid tumor cancers; and GTB-5550, a single-chain tri-specific scFv recombinant fusion protein conjugate for the treatment of B7H3+ solid tumor cancers. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Beverly Hills, California.",0,0,0
EYPT,EyePoint Pharmaceuticals Inc,Common Stock,8.55,$237.40M,https://finance.yahoo.com/quote/EYPT/profile?p=EYPT,"EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.",0,0,0
ACET,Adicet Bio Inc,Common Stock,7.57,$238.29M,https://finance.yahoo.com/quote/ACET/profile?p=ACET,"Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors, including hepatocellular carcinoma, gastric cancer, and squamous cell carcinoma of the lung. The company is based in Boston, Massachusetts.",0,0,0
COGT,Cogent Biosciences Inc,Common Stock,6.31,$239.29M,https://finance.yahoo.com/quote/COGT/profile?p=COGT,"Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.",0,0,0
FULC,Fulcrum Therapeutics Inc,Common Stock,7.7,$239.54M,https://finance.yahoo.com/quote/FULC/profile?p=FULC,"Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and Ã-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.",0,1,0
TNXP,Tonix Pharmaceuticals Holding Corp,Common Stock,0.7355,$240.43M,https://finance.yahoo.com/quote/TNXP/profile?p=TNXP,"Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 for the prevention of COVID-19. The company's lead CNS candidate is TNX-102 SL, a sublingual tablet formulation of cyclobenzaprine for fibromyalgia, and for the treatment of agitation in Alzheimer's disease, posttraumatic stress disorder (PTSD), and alcohol use disorder. Its products include TNX-1300 for the treatment of cocaine intoxication; TNX-601 CR for depression disorder, PTSD, and neurocognitive dysfunction from corticosteroids; and TNX-1900 for migraine and craniofacial pain treatment. Its preclinical pipeline includes TNX-1600 for PTSD, depression, and attention deficit hyperactivity disorder; TNX-1700 for gastric and pancreatic cancers; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500, a monoclonal antibody anti-CD40-L for organ transplant rejection autoimmunity; and TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome. It also develops TNX-2100, a COVID-19 skin test. It has collaboration agreements with Southern Research Institute and the University of Alberta; and Massachusetts General Hospital. The company was incorporated in 2007 and is headquartered in Chatham, New Jersey.",0,0,1
KMDA,Kamada Ltd,Common Stock,5.51,$243.40M,https://finance.yahoo.com/quote/KMDA/profile?p=KMDA,"Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; AeroBika, an OPEP device; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. Further, it distributes Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.",0,0,0
MBIO,Mustang Bio Inc,Common Stock,2.86,$247.10M,https://finance.yahoo.com/quote/MBIO/profile?p=MBIO,"Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.",0,0,0
KZR,Kezar Life Sciences Inc,Common Stock,5.14,$247.18M,https://finance.yahoo.com/quote/KZR/profile?p=KZR,"Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California.",0,1,0
PRTK,Paratek Pharmaceuticals Inc,Common Stock,5.52,$249.66M,https://finance.yahoo.com/quote/PRTK/profile?p=PRTK,"Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.",0,0,0
OVID,Ovid Therapeutics Inc,Common Stock,3.8,$252.92M,https://finance.yahoo.com/quote/OVID/profile?p=OVID,"Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which has completed Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; OV882 as a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815, a gene modulation therapy for the treatment of kinesin-family of proteins associated neurological disorder. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; strategic research collaboration with Columbia University Irving Medical Center; and license agreement with Angelini Pharma to develop and commercialize OV101 for the treatment of angelman syndrome in Europe. The company was incorporated in 2014 and is headquartered in New York, New York.",1,1,0
SURF,Surface Oncology Inc,Common Stock,6.22,$253.63M,https://finance.yahoo.com/quote/SURF/profile?p=SURF,"Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8 to deplete immuno-suppressive cells. It also develops an earlier stage program targeting regulatory T cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize antibodies that targets SRF813, as well as a clinical trial collaboration with Roche Holding AG to evaluate SRF388. Surface Oncology, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.",0,0,0
CNTG,Centogene NV,Common Stock,11.55,$256.35M,https://finance.yahoo.com/quote/CNTG/profile?p=CNTG,"Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including RT-PCR and antigen testing services. It has a strategic collaboration with Shire International GmbH and Pfizer Inc.; a collaboration agreement with Dr. Bauer Laboratoriums GmbH, Rostock by providing the medical laboratory services to perform its COVID-19 testing business activities; and a license agreement with Fraport AG to operate a test center for COVID-19 testing/diagnostics at Frankfurt Airport, Germany. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.",0,0,0
PDSB,PDS Biotechnology Corp,Common Stock,10.1,$257.25M,https://finance.yahoo.com/quote/PDSB/profile?p=PDSB,"PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.",0,1,0
VINC,Vincerx Inc,Common Stock,15.01,$258.79M,https://finance.yahoo.com/quote/VINC/profile?p=VINC,"Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in Phase I clinical trials to treat solid tumors. Its preclinical stage product candidates include VIP217 for solid tumors; VIP236 to treat multiple solid tumors; VIP943 for the treatment of leukemia and myelodysplastic syndrome; and VIP924 for treating B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.",0,0,0
ABUS,Arbutus Biopharma Corp,Common Stock,2.8,$260.25M,https://finance.yahoo.com/quote/ABUS/profile?p=ABUS,"Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.",0,0,0
CHMA,Chiasma Inc,Common Stock,4.14,$261.84M,https://finance.yahoo.com/quote/CHMA/profile?p=CHMA,"Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.",1,1,0
CERC,Cerecor Inc,Common Stock,2.75,$262.55M,https://finance.yahoo.com/quote/CERC/profile?p=CERC,"Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare and orphan diseases. The company develops monosaccharide therapies for the treatment of congenital disorders of glycosylation, such as CERC-801, CERC-802, and CERC-803. It is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of adult onset stills disease and multiple myeloma, as well as for the treatment of systemic juvenile idiopathic arthritis; CERC-006, an oral mTORC1/2 inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody that is in phase 2 clinical trial for the treatment of COVID-19 acute respiratory distress syndrome, as well as for the treatment of pediatric-onset Crohn's diseases. In addition, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. Cerecor Inc. has a collaboration agreement with The Frontiers in Congenital Disorders of Glycosylation Consortium on pivotal trial of CERC-801 for the treatment of Phosphoglucomutase-1 deficiency related congenital disorders of glycosylation. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.",0,1,0
ENOB,Enochian Biosciences Inc,Common Stock,5.02,$263.40M,https://finance.yahoo.com/quote/ENOB/profile?p=ENOB,"Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.",0,0,0
AMPE,Ampio Pharmaceuticals Inc,Common Stock,1.42,$263.77M,https://finance.yahoo.com/quote/AMPE/profile?p=AMPE,"Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunology-based therapies for the treatment of prevalent inflammatory conditions in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-016, an intravenous treatment that is in Phase I/II clinical trial for COVID-19 patients with respiratory illness; and AP-014, an inhaled treatment that is in Phase I clinical trial for COVID-19 induced respiratory distress. The company is headquartered in Englewood, Colorado.",1,1,0
INLB,Item 9 Labs Corp,Common Stock,2.89,$264.64M,https://finance.yahoo.com/quote/INLB/profile?p=INLB,"Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers products through licensed dispensaries to consumers in Arizona. The company is headquartered in Phoenix, Arizona.",0,0,0
NXTC,NextCure Inc,Common Stock,7.21,$265.23M,https://finance.yahoo.com/quote/NXTC/profile?p=NXTC,"NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; and NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. NextCure, Inc. has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.",0,1,0
JNCE,JOUNCE THERAPEUTICS INC,Common Stock,5.42,$265.26M,https://finance.yahoo.com/quote/JNCE/profile?p=JNCE,"Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-4014, an anti-PD-1 antibody for combination therapy; JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.",0,1,0
FREQ,Frequency Therapeutics Inc,Common Stock,8.02,$268.96M,https://finance.yahoo.com/quote/FREQ/profile?p=FREQ,"Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.",0,1,0
SEOVF,Sernova Corp,Common Stock,1.0496,$269.04M,https://finance.yahoo.com/quote/SEOVF/profile?p=SEOVF,"Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch System and associated technologies, including the cell pouch and systemic and/or locally immune protected therapeutic cells and tissues. Its Cell Pouch system is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells or tissues for the treatment of chronic diseases, such as diabetes, hemophilia, and hypothyroid disease. The company has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected universal therapeutic cells. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.",0,0,0
EIGR,Eiger BioPharmaceuticals Inc,Common Stock,8.26,$269.91M,https://finance.yahoo.com/quote/EIGR/profile?p=EIGR,"Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.",1,1,0
IBIO,iBio Inc,Common Stock,1.3,$270.13M,https://finance.yahoo.com/quote/IBIO/profile?p=IBIO,"iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.",0,0,0
CBAY,Cymabay Therapeutics Inc,Common Stock,4.1,$273.22M,https://finance.yahoo.com/quote/CBAY/profile?p=CBAY,"CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics; and CB-0406, which is in Phase I clinical trial for the inflammation disease/condition. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.",0,1,0
CTXR,Citius Pharmaceuticals Inc,Common Stock,1.98,$274.01M,https://finance.yahoo.com/quote/CTXR/profile?p=CTXR,"Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.",1,1,0
SLGL,Sol Gel Technologies Ltd,Common Stock,12.09,$276.34M,https://finance.yahoo.com/quote/SLGL/profile?p=SLGL,"Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo. The company was incorporated in 1997 and is headquartered in Ness Ziona, Israel.",1,1,0
NMTR,9 Meters Biopharma Inc,Common Stock,1.12,$276.51M,https://finance.yahoo.com/quote/NMTR/profile?p=NMTR,"9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on patients with rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease, as well as for undisclosed rare diseases and/or unmet needs. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease; and NM-002, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that is in Phase 2 clinical trial to treat SBS. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. 9 Meters Biopharma, Inc. has a collaboration with the Duke Clinical Research Institute to support the clinical development of NM-002. The company is headquartered in Raleigh, North Carolina.",1,1,0
MRMD,MariMed Inc,Common Stock,0.86035,$277.51M,https://finance.yahoo.com/quote/MRMD/profile?p=MRMD,"MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. It offers cannabis genetics produce flowers and concentrates under the Nature's Heritage brand; cannabis-infused products in the form of chewable tablets and drink powder mixes under the brand Kalm Fusion; and natural fruit chews under the Betty's Eddies brand, and cannabidiol formulations under the Florance brand. It also licenses its brands and product formulations, as well as leases cannabis facilities. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.",0,0,0
IMPL,Impel NeuroPharma Inc,Common Stock,12.66,$281.35M,https://finance.yahoo.com/quote/IMPL/profile?p=IMPL,"Impel NeuroPharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.",0,0,0
WVE,Wave Life Sciences Ltd,Common Stock,5.82,$284.27M,https://finance.yahoo.com/quote/WVE/profile?p=WVE,"Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It develops WVE-120101 and WVE-120102, a stereopure therapeutic candidates, which are in Phase 1b/2a clinical trials for the treatment of Huntington's disease (HD); WVE-003, mutant huntingtin SNP3 program for the treatment of HD; WVE-004, C9orf72 program for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-N531, our Exon 53 program for the treatment of Duchenne muscular dystrophy; and ATXN3 program in SCA3. The company has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, and University of Massachusetts. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.",0,0,0
SYRS,Syros Pharmaceuticals Inc,Common Stock,4.88,$285.17M,https://finance.yahoo.com/quote/SYRS/profile?p=SYRS,"Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors; and SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.",1,1,0
MEIP,MEI Pharma Inc,Common Stock,2.88,$285.98M,https://finance.yahoo.com/quote/MEIP/profile?p=MEIP,"MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.",0,1,0
GMDA,Gamida Cell Ltd,Common Stock,5.23,$286.15M,https://finance.yahoo.com/quote/GMDA/profile?p=GMDA,"Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.",1,1,0
INMB,INmune Bio Inc,Common Stock,17.94,$290.67M,https://finance.yahoo.com/quote/INMB/profile?p=INMB,"INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in La Jolla, California.",0,0,1
CLSD,Clearside Biomedical Inc,Common Stock,5.12,$291.93M,https://finance.yahoo.com/quote/CLSD/profile?p=CLSD,"Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.",0,0,0
CELC,Celcuity Inc,Common Stock,20.48,$295.12M,https://finance.yahoo.com/quote/CELC/profile?p=CELC,"Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.",0,0,0
VRCA,Verrica Pharmaceuticals Inc,Common Stock,11.1,$295.75M,https://finance.yahoo.com/quote/VRCA/profile?p=VRCA,"Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; which has completed phase II clinical trial for treating common warts; and that is in phase II clinical trial for the treatment of external genital warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.",0,1,0
HITI,High Tide Inc,Common Stock,6.13,$299.34M,https://finance.yahoo.com/quote/HITI/profile?p=HITI,"High Tide Inc. operates as a vertically-integrated company in the cannabis market in Canada, the United States, and internationally. It engages in the design, manufacture, and distribution of smoking accessories and cannabis lifestyle products. It is also involved in the wholesale and retailing of cannabis products, as well as operates and franchises licensed retail cannabis stores. In addition, the company provides data analytics services, as well as operates Grasscity.com and CBDcity.com platforms. As of June 3, 2021, it operated 88 retail locations in Canada. The company was formerly known as High Tide Ventures Inc. and changed its name to High Tide Inc. in October 2018. High Tide Inc. was founded in 2009 and is headquartered in Calgary, Canada.",0,0,0
FBIO,Fortress Biotech Inc,Common Stock,3.21,$299.74M,https://finance.yahoo.com/quote/FBIO/profile?p=FBIO,"Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in New York, New York.",0,0,0
AVRO,AVROBIO Inc,Common Stock,7.57,$299.88M,https://finance.yahoo.com/quote/AVRO/profile?p=AVRO,"AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's lead product candidate is AVR-RD-01, a gene therapy which is in ongoing company-sponsored Phase 2 clinical trial and investigator-sponsored Phase 1 clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in Phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; AVR-RD-04 that is in investigator-sponsored Phase 1/2 clinical trial to treat cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage to treat Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.",0,1,0
